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                                           1. GENERAL INTRODUCTION 
Medicinal Chemistry is a science whose roots lie in all branches of Chemistry and 
Biology. The practice of Medicinal Chemistry is devoted to the discovery and 
development of new agents for treating diseases. Medicinal Chemistry occupies a 
strategic position at the interface of Chemistry and Biology.  
 The earliest drug discoveries were made by the presumably random sampling 
of higher plants. However in recent year the introduction of new synthetic 
pharmaceuticals has out placed that of natural products. 
 Hundreds of thousands of new organic chemicals are prepared annually throughout 
the world, and many of them are entered into pharmacologic screens to determine if 
they have useful biologic activity. This process of random screening is inefficient, but 
it has resulted in the identification of new lead compounds not produced naturally or 
imagined by chemists. 
 Once of new pharmaceutical lead compound has been discovered, extensive 
and costly efforts usually are made to prepare a series of analogue in the hope that 
even better activity will be found such programs included the branching, lengthening 
or shortening of chain structure, the variation of the kinds and positions of 
substituents, the replacement of rings by similar cyclic structures and other empirical 
molecular modifications within the framework of reasonably close analogy. 
                                 Quinoxalinones –an outlook 
Quinoxalinone is well known for its broad coverage in the field of medicine as well as 
for its application in the pharmaceuticals. Quinoxalinone and its derivative have 
shown wide range of   biological properties such as antimicrobial, antitubercular, 
antiprotozoal, anticandida, anti-AIDS activities. Quinoxalin-2-ones display interesting 
biological properties, including the inhibition of the Aldose reductase enzyme, partial 
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agonists for complex receptors γ-aminobutyricacid(GABA)/benzodiazepine2, potent 
antithrombotic  
               
N
N                         
N
N
H
O
     
                   quinoxaline                           quinoxaline-2(1H) one     
 Quinoxaline, also called a benzopyrazine, in organic chemistry, is a heterocyclic 
compound containing a ring complex made up of benzene ring and pyrazine ring and 
they are isomeric with cinnolenes, phthalazines and quinazolines. Synthetic 
quinoxaline moiety is a part of number of antibiotics such as echinomycin, levomycin 
and actinomycin.  
 Quinoxaline and its derivatives have shown wide range of biological 
properties such as Antimicrobial, Antibacterial, Antitubercular, Antiprotozoal, Anti-
candida, Anticancer, Anti- AIDS, and Antiinflammatory  
                            4-Thiazolidinones-An outlook 
Thiazolidinones are the derivatives of thiazolidine which belong to an important 
group of heterocyclic compounds containing sulfur and nitrogen in a five member 
ring. A lot of research work on thiazolidinones has been done in the past. The nucleus 
is also known as wonder nucleus because it gives out different derivatives with all 
different types of biological activities. antimicrobial, anticonvulsant , analgesic, anti-
inflammatory, anticancer, Follicle stimulating hormone (FSH) receptor agonist 
activity and CFTR inhibitor The cystic fibrosis transmembrane conductance regulator 
(CFTR) is a cAMP-regulated chloride channel,which when mutated can produce the 
hereditary disease cystic fibrosis. CFTR inhibition is a potential strategy for therapy 
of secretory diarrhoeas 
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 Hydrazone –An outlook 
  Hydrazone constitute an important class of compounds for new drug development. 
Hydrazones containing an azometine -NHN=CH- proton are synthesized by heating 
the appropriate substituted hydrazines/hydrazides with aldehydes and ketone in 
solvent. 
.Hydrazones have been reported to possess, antimicrobial, antitubercular 
,anticonvulsant ,analgesic, anti-inflammatory antiplatelet ,anticancer ,antifungal, 
antiviral , ,antibacterial and antimalarial  activities   
Cancer 
  Cancer (medical term: malignant neoplasm) is a class of diseases in which a group of  
cells display uncontrolled growth (division beyond the normal limits), invasion  
(intrusion on and destruction of adjacent tissues), and sometimes metastasis (spread to  
other locations in the body via lymph or blood). These three malignant properties of 
cancers differentiate them from bengin tumours, which are self-limited, and do not  
invade or metastasize.  
What causes cancer? 
• Cancer arises from the mutation of a normal gene. 
• Mutated genes that cause cancer are called oncogenes. 
• It is thought that several mutations need to occur to give rise to cancer 
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• Cells that are old or not functioning properly normally self destruct and are 
replaced by new cells. 
• However, cancerous cells do not self destruct and continue to divide rapidly 
producing millions of new cancerous cells. 
• A factor which brings about a mutation is called a mutagen. A mutagen is 
mutagenic. Any agent that causes cancer is called a carcinogen and is 
described as carcinogenic. So some mutagens are carcinogenic. 
   carcinogens: 
• Ionising radiation – X Rays, UV light 
• Chemicals – tar from cigarettes 
• Virus infection – papilloma virus can be responsible for cervical cancer. 
• Hereditary predisposition – Some families are more susceptible to getting 
certain cancers, it cannot be inherited just that more susceptible to getting it. 
Classification 
 Cancer are classified by the type of cell that resembles the tumor and, 
therefore, the tissue presumed to be the origin of the tumor. These are the 
histology and the location, respectively. Example of general categories includes: 
• Carcinoma: Malignant tumors derived from epithelial cells. This group 
represents the most common cancers, including the common forms of breast, 
prostate, lung and colon cancer. 
• Sarcoma: Malignant tumors derived from connective tissue, or mesenchymal 
cells. 
• Lymphoma and leukaemia: Malignancies derived from hematopoietic 
(blood-forming) cells. 
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• Germ cell tumor: Tumor derived from totipotent cells. In adults most often 
found in the testicle and ovary; in foetuses, babies and young children most 
often found on the body midline, particularly at the tip of the tailbone; in 
horses most often found at the poll(base of the skull). 
• Blastic tumor or blastoma: A tumor (usually malignant) which resembles an 
immature or embryonic tissue. Many of these tumors are most common in 
children. 
                Malignant tumors (cancers) are usually named using –carcinoma, -
sarcoma or –blastoma as a suffix, with the Latin or Greek word for the organ of 
origin as the root. For instance, a cancer of the liver is called hepatocarcinoma; a 
cancer of the fat cells is called liposarcoma. For common cancers, the English organ 
name is used. For instance, the most common type of breast cancer is called ductal 
carcinoma of the breast or mammary ductal carcinoma. Here, the adjective ductal 
refers to the appearance of the cancer under the microscope, resembling normal breast 
ducts.  
Benign tumors (which are not cancers) are named using –oma as a suffix with the 
organ name as the root. For instance, a benign tumor of the smooth muscles of the 
uterus is called leiomyoma (fibroid). 
     
 
 
 
 
            
 
 
                            
Introduction 
 
Dept. of Pharmaceutical Chemistry, MMC, Madurai Page 6 
 
    STAGES INVOLVED IN THE DEVELOPMENT OF CANCER 
   1. Normal cell           2. Mutation of DNA 
 
     3.Genetically altered cell   4. Spread and second mutation 
 
5. Third mutation    6. Fourth mutation 
 
7   Breaking through the membrane         8. Angiogenesis 
   
                                           9 Invasion and Dispersal 
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1. DNA of a normal cell 
 This piece of DNA is an exact copy of the DNA from which it came. When 
the parent cell divided to create two cells, the cell's DNA also divided, creating 
two identical copies of the original DNA.  
     2. Mutation of DNA 
With this section of DNA, one of the base pairs is different from the original. This 
DNA has suffered a mutation, either through mis-copying (when its parent cell 
divided), or through the damaging effects of exposure to radiation or a chemical 
carcinogen. 
         3. Genetically altered cell 
Body cells replicate through mitosis. The DNA of the cell highlighted above has a 
mutation that causes the cell to replicate even though this tissue doesn't need 
replacement cells at this time or at this place. 
    4. Spread and second mutation  
   The genetically altered cells (look like normal cell and carry two mutant gene)                           
have, overtime, reproduced unchecked, crowding out the surrounding normal 
cells. The growth may contain one million cells. 
5. Third mutation 
  A mutation may simply cause a cell to keep from self-destructing. All normal 
cells have surveillance mechanisms that look for damage or for problems with 
their own control systems. If such problems are found, the cell destroys itself. 
Over time and after many cell divisions, a third mutation may arise.  
6. Fourth mutation 
 At this point the next mutation paves the way for the development of an even 
more aggressive cancer 
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7. Breaking through the membrane 
The newer, wilder cells created by another mutation are able to push their way 
through the epithelial tissue's basement membrane. At this point the cancer is still 
too small to be detected 
8. Angiogenesis 
 The tumour has broken through the basement membrane (as pictured above), 
angiogenesis takes place.Angiogenesis is the recruitment of blood vessels from 
the network of neighbouring vessels. 
9. Invasion and Dispersal 
 Individual cells from the tumour enter into the network of newly formed blood 
vessels, using these vessels as highways by which they can move to other parts of 
the body.  
10. Metastasis 
 To form a secondary tumour, a tumour cell needs to leave the vessel system 
and invade tissue. The cell must attach itself to a vessel's wall. Once this is done, 
it can work its way through the vessel and enter the tissue.  Although perhaps less 
than one in 10,000 tumour cells will survive long enough to establish a new 
tumour site, a few survivors can escape and initiate new colonies of the cancer. 
Signs and Symptoms 
Symptoms of cancer metastasis depend on the location of the tumor. 
Roughly, cancer symptoms can be divided into three groups: 
• Local symptoms: Unusual lumps or swelling (tumor), hemorrhage (bleeding), 
pain and/or ulceration. Compression of surrounding tissues may cause 
symptoms such as jaundice (yellowing the eyes and skin). 
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• Symptoms of metastasis (Spreading): Enlarged lymph nodes, cough and 
hemoptysis, hepatomegaly (enlarged liver), bone pain, fracture of affected 
bones and neurological symptoms. Although advanced cancer may cause pain, 
it is often not the first symptom. 
• Systemic symptoms: Weight loss, poor appetite, fatigue and cachexia 
(wasting), excessive sweating (night sweats), anaemia and specific 
paraneoplastic phenomena, i.e. specific conditions that are due to an active 
cancer, such as thrombosis or hormonal changes. 
Every symptom in the above list can be caused by a variety of conditions (a list of 
which is referred to as the differential diagnosis). Cancer may be a common or 
uncommon cause of each item. 
Anti-microbial drugs 
The control of microorganism is critical for the prevention and treatment of 
disease. Microorganisms also grow on and within other organism, and microbial 
colonization can lead to disease, disability, and death. Thus the control or 
destruction of microorganisms residing within the bodies of humans and other 
animals is great importance.  
Antibiotics are chemical substances excreted by some microorganism which 
inhibit the growth and development of other microbes. Some of these drugs that 
were obtained naturally were put to chemical modifications in attempts to enhance 
beneficial effects while minimizing the toxic effects. The resultant modified 
product is termed as semi synthetic antibiotics. Most antibiotic currently used are 
semi synthetic. The chemist has synthesized many drugs that have got the 
antibacterial property and less toxicity. These drugs are called synthetic antibiotic 
drugs. Naturally occurring antibiotics, their semi synthetic derivatives and 
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synthetic antibiotics have got the same target. i.e., antimicrobial  action. Hence all 
these drugs were put together to be called antimicrobial agents. 
General Characteristics of Antimicrobial Drugs: 
A successful chemotherapeutic agent must have selective toxicity. It must kill 
or inhibit the microbial pathogen while damaging the host as little as possible. The 
degree of selective toxicity may be expressed in following terms. 
a) The therapeutic dose, the drug level required for clinical treatment of a 
particular infection. 
b) The toxic dose, the drug level at which the agent becomes too toxic for the 
host. 
The therapeutic index is the ratio of the toxic dose to the therapeutic dose. The 
larger the therapeutic index, the better the chemotherapeutic agent 
Thus anti-microbial  are divided in to 
1. Antibacterial drugs 
2. Antiviral drugs 
3. Antifungal drugs 
4. Antiprotozoal drugs 
5. Anthelmintic drugs. 
Chemotherapeutic agents can be either bactericidal or bacteriostatic. 
Introduction to anti-inflammatory drugs 
In order to screen new potential anti-inflammatory-anti-arthritic compounds, one must 
have clear understanding about the prime cause of inflammation, the nature of 
inflammation, target organ involved, various stages of inflammation, biochemical and 
other systemic changes due to inflammation. 
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Inflammation may broadly classify into three categories: 
(1) Acute inflammation. 
                    When a tissue injury is caused by a single event such as mechanical 
trauma, a thermal or chemical burn or a single exposure to non-replicating antigen the 
protective phenomena results in inflammation and repairative process proceeds 
smoothly from injury to recovery. 
(2) Chronic inflammation. 
                    There are many diseases which are distinguished by signs and symptoms 
characteristic of response to chronic inflammatory process of unknown etiology ss 
Ex: rheumatic fever, rheumatoid arthritis, ankylosing spondylitis and osteoarthritis, 
(3) Miscellaneous kinds of inflammation. 
            This category may include allergic and dermatological disorders. 
                       NSAIDs are used primarily to treat inflammation, mild to moderate 
pain, and fever. Specific uses include the treatment of headaches, arthritis, sports 
injuries, and menstrual cramps Aspirin (also an NSAID) is used to inhibit the clotting 
of blood and prevent strokes and heartattacks in individuals at high risk. NSAIDs also 
are included in many cold and allergy preparations. 
Mechanism of  NSAIDS 
Prostaglandins are produced within the body's cells by the enzyme cyclooxygenase 
(COX). There are two COX enzymes, COX-1 and COX-2. Both enzymes produce 
prostaglandins that promote inflammation, pain, and fever. However, only COX-1 
produces prostaglandins that support platelets and protect the stomach. Nonsteroidal 
antiinflammatory drugs (NSAIDs) block the COX enzymes and reduce prostaglandins 
throughout the body. As a consequence, ongoing inflammation, pain, and fever are 
reduced. Since the prostaglandins that protect the stomach and support platelets and 
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blood clotting also are reduced, NSAIDs can cause ulcers in the stomach and promote 
bleeding. 
The events of the inflammtory response and mechanisms of anti-flammatory 
Phospholipase
Arachidonic acid
Cyclooxygenase Lipoxygenases
Steroids-----
NSAIDs -----
Prostaglandins
PGE2PGF2α PGI2
pyrexia vasodilationalgesic
PMNs
Lymphokines
-----
Lipoxygenase inhititors
The events of the inflammtory response and mechanisms of anti-flammatory
 
 
Thus attempt is made to review the inflammation, various factors involved in the 
inflammatory process, available methods for screening potential anti-inflammatory 
agents which would come near enough to steroids without any deleterious effects. and 
finally future trend of research in the field of inflammation or connective tissue dis-
orders. 
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2. Literature Review 
                                           
Anti cancer activity  
1)  Moarbess G., et al., were assessed  In-vitro cytotoxicity studies against melanoma 
(A375, M4Be, and RPMI-7591), colon (LS174T), breast (MCF7), and lymphoma 
(Raji) human cancer cell lines. In vivo studies were carried out in M4Be xenografted 
athymic mice. EAPB (I), EAPB (II), EAPB (III), showed significant in 
vitro activities against A375 compared to fotemustine and imiquimod used as 
references. 
 
               Substituted pyrazolo[1,5-a]quinoxaline 
Where, R1=(CH3)2–CH–CH2–,C6H5–(CH2)2–andR4=CH3–NH–NH2         
            
2) Weng Q., et al., Synthesized compounds a and   showed that 3-(4-bromophenyl)-2-
(ethylsulfonyl)-6-methylquinoxaline 1,4-dioxide (Q39), derived from Quinoxaline 
1,4-Di-N-oxide, possessed high anti-cancer activity in hypoxia. Cytotoxicity assay 
demonstrated that Q39 is a potential and high efficient anti-cancer compound in all 
tested cell. In their work showing the mechanism of Q39 in hypoxia. 
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Chemical structure of Q39 
3) Masquefa C., et al .,were synthesized New series of  imidazo[1,2-a]quinoxaline 
analogues have been in good yields via a bimolecular condensation of 2-imidazole 
carboxylic acid, followed by a coupling with ortho-fluoroaniline and subsequent 
substitution on the imidazole ring by Suzuki Cross-coupling reaction using 
microwave assistance. Antitumor activities of these derivatives were evaluated by 
growth inhibition of A375 cells in vitro.  It was proposed that all compounds 
exhibited high activities compared to imiquimod and fotemustine used as reference.  
 
Where, R= (CH3)2CHCH, R= C6H5 (CH2)2 
 Iimidazo [1, 2-a]quinoxaline analogues 
4) Stuart T. Hazeldine., et al., carried out Synthetic modification of the 2-
oxypropionic acid moietyin 2-{4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy}propionic 
acid (XK469).All halogenated derivatives of above showed  to be active antitumor 
activity of colon cancer cells 
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N
N O
O
COOHCH3
X
 
X= Cl,F,Br,I 
5) Paloa  Caronoa., et al., synthesized 5,7-diamino-3- phenyl-2-benzylamino, 2-
phenoxy and 2-phenylthio substituted quinoxalines. The compound 1b-6b exhibited 
better anticancer activity for lung, breast cancer cells. 
N
N
NH2
NH2 NH
R
2
R
1
R  
1b: R = R2 = H; R1 = OCH3 
2b: R = R2 = OCH3; R1 = H 
3b: R = R1 = OCH3; R2 = H 
4b: R = R1 = R2 = OCH3 
5b: R = R1 = Cl; R2 = H 
6b: R = R2 = H; R1 = F 
7b: R = R2 = H; R1 = CO-Glu-Et 
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Anticonvulsant activity 
6) Rantnadee v.ghadge .,et al., Synthesized  Schiff’s bases of 3-{[2-({(E) 
- [(substituted) phenyl] methylidene} amino) ethyl] amino} quinoxalin-2(1H)-one 
were evaluated  for anticonvulsant activity  screening  showed a generally good 
activity  with 2- nitro group substituted derivative 
N
N
H
O
NH
N
Ar
-
 
Ar =C6H5CHO, 2NO2C6H5CHO, 3NO2C6H5CHO, OHC12H8CHO, 4OCH3C6H5CHO 
 
7)Wagle S., et al., synthesized N-arylidenehydrazino quinoxalines. Further, the 
oxidative cyclizations of hydrazones by nitrobenzene yielded the synthesized 
compounds were showed anti-convulsant activity. 
 
Where, R=H, CH3, CF3, (Un) substituted phenyl, R1= (UN) substituted phenyl 
 1-aryl-4-methyl [1,2,4] triazolo[4,3-a]quinoxalines. 
Anti-tubercular activity: 
8) Vicente E., et al., evaluated for in vitro efficacies of the 1,4-di-N-oxide quinoxaline 
derivatives against Mycobacterium tuberculosis and has lead to the discovery of a 
derivative with in vivo efficacy in the mouse model of tuberculosis 
                                                                                                       Literature Review 
 
Dept. of Pharmaceutical Chemistry, MMC, Madurai Page 17 
 
 
Where, R1/R2= H/CH3,H/OCH3, H/H, H/Cl, F/F, Cl/Cl,CH3/CH3, H/F, H/CF3 
R3= CH2CH3, CH2Ph, CH3 
9) Carta A., et al., synthesized 6-(7)-substituted-3-methyl- or 3-halogenomethyl-2 
phenylthio–phenylsulphonyl–chloro-quinoxaline 1,4-dioxides derivatives were 
evaluated for in vitro antimycobacterial and Antitubercular screening showed a 
generally good activity of 3-methyl-2-phenylthioquinoxaline 1,4-dioxides against 
Mycobacterium tuberculosis 
 
Where, R=Cl,S-Ph,SO2Ph, R1=H,Br and R2/R3=H, Cl,F,,CF3,CH3 
 3-halogenomethyl-2phenylthio–phenylsulphonyl–chloro-quinoxaline 1, 4-dioxides 
10) Jaso A., et al., synthesized A series of 2-acetyl and 2-benzoyl-6(7)-substituted 
quinoxaline 1, 4-di-N-oxide derivatives were evaluated for in vitro antituberculosis 
activity. The results show that 2-acetyl-3-methylquinoxaline 1,4-di-N-oxide 
derivatives with chlorine, methyl or methoxy group in position 7 of 
the benzene moiety and unsubstituted  have good antitubercular activity. 
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Where, R1=Cl, CH3, R2=Cl, H, R3 andR4=CH3 
 2-acetyl and 2-benzoyl-6(7)-substituted quinoxaline 1, 4-di-N-oxide derivatives 
Antifungal   activity 
11)Carta A. ,et al., synthesized (7)-substituted-3-methyl- or 3-halogenomethyl-2 
phenylthio–phenylsulphonyl–chloro-quinoxaline 1, 4-dioxides.this derivatives were 
found to be good  antimycobacterial and anticandida activity 
 
Where,  R= Cl,S-Ph,SO2Ph, R1= H, Br and R2/R3= H, Cl,F,,CF3,CH3 
 (7)-substituted-3-methyl- or 3-halogenomethyl-2 phenylthio–phenylsulphonyl -
quinoxaline 1, 4-dioxides 
 Anti-malarial activity 
    12)Vicente E. ,et al .,reported 3-phenylquinoxaline 1,4-di-N-oxide derivatives have 
been Antiplasmodial activity vitro against Plasmodium falciparum by the 
incorporation of [3H]-hypoxanthine. Some of them were shown to be more active 
than chloroquine in the resistant strain 
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  3-phenylquinoxaline 1,4-di-N-oxide derivatives 
 
SRPK-1 kinase inhibitor 
13)Szekelyhidi Z.,et al., synthesized novel tricycle quinoxaline derivatives and 
synthesized as potential kinase inhibitory antiviral agents and were found to be active 
and selective for SRPK-1 kinase.  
 
 Tricyclic quinoxaline derivatives 
 Adenosine A1 receptor inhibitory activity 
14)Liu C., et al., Synthesized 4-alkylamino-1-hydroxymethylimidazo [1,2-
a]quinoxalines have been synthesized and evaluated for their adenosine 
A1 receptor inhibitory activity in the radioligand binding assays. The compounds 
were tested for the inhibition percent (IP) and the affinity toward A1AR (Ki) that IP 
were more than 90% in the nanomolar ranges.  
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Where, R1=H and R2= (CH3)2CH2CH2- 
 4 -alkylamino-1-hydroxymethylimidazo [1,2-a]quinoxalines 
Poly- (ADP-ribose) polymerase-1,2 inhibitor: 
15)Iwashita A., et al .,were identified as potent and selective poly- (ADP-ribose) 
polymerase-1 and 2 (PARP-1) and (PARP-2) inhibitors, respectively. In PARP 
enzyme assays using recombinant PARP-1 and PARP-2, quinazolinone derivatives 
displayed relatively high selectivity for PARP-1 and quinoxaline derivatives showed 
superior selectivity for PARP-2. SBDD analysis via a combination of X-ray structural 
study and homology modeling suggested distinct interactions of inhibitors with 
PARP-1 and PARP-2. These findings provide a new structural framework for the 
design of selective inhibitors for PARP-1 and PARP-2.  
 
Where R= H, NH2, Cl, OMe 
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HIV-1 inhibitor 
16) (S) - 4 - isopropoxycarbonyl- 6 - methoxy-3- (methylthiomethyl)-
3,4dihydroquinoxaline-2(1H)-thione (HBY 097) was used to select for drug-resistant 
HIV-1 variants in vitro. The viruses first developed mutations affecting the NNRTI 
binding pocket, and five of six strains displayed the RT G190-E substitution, which is 
characteristic for HIV-1 resistance against quinoxalines.  
 
Structure of (HBY 097) 
 Analgesic and anti-inflammatory activities: 
17)Hashem A., et al., demonstrated analgesic and anti-inflammatory activities of 2-
aminopyrimido [thiazolo[4,5-b]quinoxaline-4-one. Some of these compounds 
exhibited promising activities. 
 
Where, R= F, H, CH3O 
 2-aminopyrimido [thiazolo[4,5-b]quinoxaline-4-one. 
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18)Singh,DharmchandPrasad., et al., Some New Thio-Ether Derivatives of 
Quinoxaline and evaluated for anti-inflammatory activity. The compound substituted 
with cl showed good anti inflammatory 
 
N
N
CH3
S CONH
R
 
2-(2-methylquinoxalin-3-ylthio)-N-substitutedphenyl)acetamides 
R=2-Cl;3-Cl;4-Cl;4-Br;4-CH3 4-OCH3 ;3-Cl 4-F;2-CH3 3-CH3 2-COOCH3 
19) Asuncio ´n Burguete., et al., Synthesized somenew ring substituted 3-phenyl-
1-(1,4-di-N-oxide quinoxalin-2-yl)-2-propen-1-one derivatives and evaluated for anti-
inflammatory activity. The result  showed compound of R=H exhibited good anti -
inflammatory activity 
R N
N
O
O
OH
O-
O-
 
where R=H  R=F  R=CH3O 
20) SMD Noorulla.,et al.,  synthesized some novel substituted quinoxaline 
heterocycle nucleus .The antiinflammatory activity  were conducted . the presence of 
OCH3 on phenyl nucleus attached to second position of the quinoxaline nucleus may 
be responsible for marked anti-inflammatory activity.  
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N
N
NH
NH
N
NH O
N
R
 
R= O-OCH3, p- OH, m-NO2, m-OH, P-OCH3 
 
PDGF-R inhibitor 
 21)Myers M., et al., Demonstrated activity novel substituted 2-anilino- and 2-
cycloalkylaminoquinoxalines as inhibitors of PDGF-R autophosphorylation. The 
found that Replacement of an anilino-substituent with substituted cyclohexylamino- 
or norbornylamino substituents lead to significant improvements in the 
pharmacokinetic profile of these analogues.  
 
Where, R1=H, Me, R2= H, Me, R3 and R4= H, Me, MeO 
Antimicrobial activity 
22) Refaat H., et al., were synthesized series of 2-[4-N-2-acylhydrazinocarbonyl) 
aniline]-3-methyl quinoxalines, as well as their cyclized oxadiazolyl derivatives were 
also prepared. Some of these derivatives were evaluated for antimicrobial activity in 
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vitro. It was found that all the selected compounds exhibit antimicrobial activity and 
some of these compounds had a broad spectrum of activity.  
 
Where, Ar – 3-Br-C6H4, 4-Br-C6H4, 4-NO2-C6H4 
23) Dharmchand Prasad Singh.,et al., synthesized 2-[4-(substituted-
benziminomethyl)-phenoxy]-3-methyl quinoxalines and 4-(2-methylquinoxalin-3-
yloxy)- N-substituted benzylidine benzamines and evaluated for antimicrobial activity 
. The  compound with 3-OCH3  showed high active against E.coli 
N
N O
N
R
 
R= H; Cl; CH3; 4-COOH; 2- CH3 6- CH3        
N
N O
N
R
 
   R= 4-OH; 2-NO2 ; 4-N(CH3)2 ; 2-OH,3-OCH3 ; 2-OCH3 ,3-OCH3 ,4OCH3 
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24) Shiv Kumar., et al.,  Synthesized  Tetrazolo[1,5-a]quinoxaline based Azetidinones 
& Thiazolidinones  . Some of these derivatives were evaluated for antimicrobial 
activity in vitro. It was found that all the selected compounds exhibit antimicrobial 
activity and some of these compounds had a broad spectrum of activity. 
 
N
N
N
N
NH
NH
N
S
O
R  
R=C6H5, 0-Cl C6H4,O-F C6H4,O-NO2 C6H4,P-ClC6H4,P-F C6H4 ,P-NO2 C6H4 
 
 25) Rantnadee v.ghadge. et al., Synthesized  Schiff’s bases of 3-{[2-({(E) 
-[(substituted) phenyl] methylidene} amino) ethyl] amino}quinoxalin-2(1H)-one  
were evaluated  for  antimicrobial  activity  screening  showed a generally all 
compound are more active against p.aerogenosa  
N
N
H
O
NH
N
Ar
-
 
Ar=3-Cl-C6H5CHO, 3,4,CLC6H3CHO, (CH3)2N-C6H5CHO, OHC12H8CHO 
 26) SMD Noorulla.,et al.,  synthesized some novel substituted quinoxaline 
heterocycle nucleus .The antibacterial tests were conducted on four common 
microorganisms such as Bacillus subtilis, Staphylococcus aureus , Escherichia coli 
and Klebsiella pneumoniae .The synthesized  compound found to be active against 
Bacillus subtilis. 
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N
N
NH
NH
N
NH O
N
R
 
R=p-OCH3, P- OH, m-NO2,m-OH 
Antihistaminic activity 
 27) Sridevi C., et al., synthesized phenyl pyrazolo benzimidazole quinoxaline. 
All the synthesized compounds were screened for their antihistaminic activity.Some 
were shown good % protection of anti-histamic activity.  
 
Anti-proliferativeactivity: 
 28) Chung H., et al., were synthesized a series of 6-arylamino-2,3-bis(pyridin-
2-yl)-7-chloro-quinoxaline-5,8-diones and evaluated for their inhibitory activity on rat 
aortic smooth muscle cell proliferation. They were observed that The quinoxaline-5,8-
diones exhibited a potent anti-proliferative activity.  
 
 6-arylamino-2, 3-bis(pyridin-2-yl)-7-substituted -quinoxaline-5,8-diones 
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                                        Review of reaction 
 
The  various method of preparation of some  substituted quinoxaline-2(1H)-one 
derivative by phillip’s condensation mechanism 
 
I)Condensation of oxalic acid  with o-phenylenediamine 
NH2
NH2
+
OH
OHO
O
stirring,15min
∆ 100 °C
N
H
N
H
O
O
o-phenylene 
diamine oxalic acid
1,4-dihydroquinoxaline-2,3-dione
 
 
2)One-pot efficientgreen synthesis of 1,4-dihydro-quinoxaline-2,3-dione 
                     
+
O OH
OHO
RT
GRINDING
NH2
NH2
N
H
N
H
O
O
A A
B
B
 
 
3)Gris J et al29 has carried out the microwave-assisted Hinsberg reaction of 
quinoxalinone derivatives 
+
O OH
OHR
NH2
NH2
N
H
N
O
R
S. cereviciae
MW Irradiation
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4) Various quinoxaline-2,3-diones32 were synthesized by rotatory  
evaporation of 1,2-diamino aromaticcompounds in diethyl oxalate .           
+
NH
NH2
R
Cl
OH
OH
O
O
R
N
N
H
O
O
Cl
rotavapour
50-80 °C
 
One of the most  features  in quinoxaline-2(1H)-one  chemistry is their use as key 
starting materials for further transformation. The reaction of ethylene diamine  
with quinoxaline-2(1H)-one   results in the formation of 3-[(2-
aminoethyl)amino]quinoxalin-2(1H)-one 
3-[(2-aminoethyl)amino]quinoxalin-2(1H)-one could be used as versatile  building 
blocks in the synthesis of new heterocyclic systems 
Thus the present work is in conjuction  with the reaction of the  amino 
functionality of 3-[(2-aminoethyl)amino]quinoxalin-2(1H)-one with carbon 
electrophiles namely substituted aromatic aldehydes  
 
N
N
H
N H
N H 2
O
N
N
H
N H
N
O
A r
-
ArCHO,EtOH
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The nucleophilic attack of the amino group on the electronically deficient 
carbonyl carbon atom of  the aldehyde , followed by dehydration results in the 
formation of Schiff bases 
As mentioned earlier , 4-Thiazolidinones are reported to possess a variety of 
therapeutic activities. 
Taking in to this consideration .,Cyclocondensation of Schiff's bases with 2-
mercaptopropionic acid afforded 4-thiazolidinone derivatives, 
 
N
N
H
NH
N
O
Ar
-
Thiog lyco lic  ac id ,dm f
zinc  chlor ide
N
N
H
NH
N
O
S
O
Ar
-
 
  
 
                                                                                                       Literature Review 
 
Dept. of Pharmaceutical Chemistry, MMC, Madurai Page 13 
 
2. Literature Review 
                                           
Anti cancer activity  
1)  Moarbess G., et al., were assessed  In-vitro cytotoxicity studies against melanoma 
(A375, M4Be, and RPMI-7591), colon (LS174T), breast (MCF7), and lymphoma 
(Raji) human cancer cell lines. In vivo studies were carried out in M4Be xenografted 
athymic mice. EAPB (I), EAPB (II), EAPB (III), showed significant in 
vitro activities against A375 compared to fotemustine and imiquimod used as 
references. 
 
               Substituted pyrazolo[1,5-a]quinoxaline 
Where, R1=(CH3)2–CH–CH2–,C6H5–(CH2)2–andR4=CH3–NH–NH2         
            
2) Weng Q., et al., Synthesized compounds a and   showed that 3-(4-bromophenyl)-2-
(ethylsulfonyl)-6-methylquinoxaline 1,4-dioxide (Q39), derived from Quinoxaline 
1,4-Di-N-oxide, possessed high anti-cancer activity in hypoxia. Cytotoxicity assay 
demonstrated that Q39 is a potential and high efficient anti-cancer compound in all 
tested cell. In their work showing the mechanism of Q39 in hypoxia. 
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Chemical structure of Q39 
3) Masquefa C., et al .,were synthesized New series of  imidazo[1,2-a]quinoxaline 
analogues have been in good yields via a bimolecular condensation of 2-imidazole 
carboxylic acid, followed by a coupling with ortho-fluoroaniline and subsequent 
substitution on the imidazole ring by Suzuki Cross-coupling reaction using 
microwave assistance. Antitumor activities of these derivatives were evaluated by 
growth inhibition of A375 cells in vitro.  It was proposed that all compounds 
exhibited high activities compared to imiquimod and fotemustine used as reference.  
 
Where, R= (CH3)2CHCH, R= C6H5 (CH2)2 
 Iimidazo [1, 2-a]quinoxaline analogues 
4) Stuart T. Hazeldine., et al., carried out Synthetic modification of the 2-
oxypropionic acid moietyin 2-{4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy}propionic 
acid (XK469).All halogenated derivatives of above showed  to be active antitumor 
activity of colon cancer cells 
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N
N O
O
COOHCH3
X
 
X= Cl,F,Br,I 
5) Paloa  Caronoa., et al., synthesized 5,7-diamino-3- phenyl-2-benzylamino, 2-
phenoxy and 2-phenylthio substituted quinoxalines. The compound 1b-6b exhibited 
better anticancer activity for lung, breast cancer cells. 
N
N
NH2
NH2 NH
R
2
R
1
R  
1b: R = R2 = H; R1 = OCH3 
2b: R = R2 = OCH3; R1 = H 
3b: R = R1 = OCH3; R2 = H 
4b: R = R1 = R2 = OCH3 
5b: R = R1 = Cl; R2 = H 
6b: R = R2 = H; R1 = F 
7b: R = R2 = H; R1 = CO-Glu-Et 
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Anticonvulsant activity 
6) Rantnadee v.ghadge .,et al., Synthesized  Schiff’s bases of 3-{[2-({(E) 
- [(substituted) phenyl] methylidene} amino) ethyl] amino} quinoxalin-2(1H)-one 
were evaluated  for anticonvulsant activity  screening  showed a generally good 
activity  with 2- nitro group substituted derivative 
N
N
H
O
NH
N
Ar
-
 
Ar =C6H5CHO, 2NO2C6H5CHO, 3NO2C6H5CHO, OHC12H8CHO, 4OCH3C6H5CHO 
 
7)Wagle S., et al., synthesized N-arylidenehydrazino quinoxalines. Further, the 
oxidative cyclizations of hydrazones by nitrobenzene yielded the synthesized 
compounds were showed anti-convulsant activity. 
 
Where, R=H, CH3, CF3, (Un) substituted phenyl, R1= (UN) substituted phenyl 
 1-aryl-4-methyl [1,2,4] triazolo[4,3-a]quinoxalines. 
Anti-tubercular activity: 
8) Vicente E., et al., evaluated for in vitro efficacies of the 1,4-di-N-oxide quinoxaline 
derivatives against Mycobacterium tuberculosis and has lead to the discovery of a 
derivative with in vivo efficacy in the mouse model of tuberculosis 
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Where, R1/R2= H/CH3,H/OCH3, H/H, H/Cl, F/F, Cl/Cl,CH3/CH3, H/F, H/CF3 
R3= CH2CH3, CH2Ph, CH3 
9) Carta A., et al., synthesized 6-(7)-substituted-3-methyl- or 3-halogenomethyl-2 
phenylthio–phenylsulphonyl–chloro-quinoxaline 1,4-dioxides derivatives were 
evaluated for in vitro antimycobacterial and Antitubercular screening showed a 
generally good activity of 3-methyl-2-phenylthioquinoxaline 1,4-dioxides against 
Mycobacterium tuberculosis 
 
Where, R=Cl,S-Ph,SO2Ph, R1=H,Br and R2/R3=H, Cl,F,,CF3,CH3 
 3-halogenomethyl-2phenylthio–phenylsulphonyl–chloro-quinoxaline 1, 4-dioxides 
10) Jaso A., et al., synthesized A series of 2-acetyl and 2-benzoyl-6(7)-substituted 
quinoxaline 1, 4-di-N-oxide derivatives were evaluated for in vitro antituberculosis 
activity. The results show that 2-acetyl-3-methylquinoxaline 1,4-di-N-oxide 
derivatives with chlorine, methyl or methoxy group in position 7 of 
the benzene moiety and unsubstituted  have good antitubercular activity. 
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Where, R1=Cl, CH3, R2=Cl, H, R3 andR4=CH3 
 2-acetyl and 2-benzoyl-6(7)-substituted quinoxaline 1, 4-di-N-oxide derivatives 
Antifungal   activity 
11)Carta A. ,et al., synthesized (7)-substituted-3-methyl- or 3-halogenomethyl-2 
phenylthio–phenylsulphonyl–chloro-quinoxaline 1, 4-dioxides.this derivatives were 
found to be good  antimycobacterial and anticandida activity 
 
Where,  R= Cl,S-Ph,SO2Ph, R1= H, Br and R2/R3= H, Cl,F,,CF3,CH3 
 (7)-substituted-3-methyl- or 3-halogenomethyl-2 phenylthio–phenylsulphonyl -
quinoxaline 1, 4-dioxides 
 Anti-malarial activity 
    12)Vicente E. ,et al .,reported 3-phenylquinoxaline 1,4-di-N-oxide derivatives have 
been Antiplasmodial activity vitro against Plasmodium falciparum by the 
incorporation of [3H]-hypoxanthine. Some of them were shown to be more active 
than chloroquine in the resistant strain 
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  3-phenylquinoxaline 1,4-di-N-oxide derivatives 
 
SRPK-1 kinase inhibitor 
13)Szekelyhidi Z.,et al., synthesized novel tricycle quinoxaline derivatives and 
synthesized as potential kinase inhibitory antiviral agents and were found to be active 
and selective for SRPK-1 kinase.  
 
 Tricyclic quinoxaline derivatives 
 Adenosine A1 receptor inhibitory activity 
14)Liu C., et al., Synthesized 4-alkylamino-1-hydroxymethylimidazo [1,2-
a]quinoxalines have been synthesized and evaluated for their adenosine 
A1 receptor inhibitory activity in the radioligand binding assays. The compounds 
were tested for the inhibition percent (IP) and the affinity toward A1AR (Ki) that IP 
were more than 90% in the nanomolar ranges.  
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Where, R1=H and R2= (CH3)2CH2CH2- 
 4 -alkylamino-1-hydroxymethylimidazo [1,2-a]quinoxalines 
Poly- (ADP-ribose) polymerase-1,2 inhibitor: 
15)Iwashita A., et al .,were identified as potent and selective poly- (ADP-ribose) 
polymerase-1 and 2 (PARP-1) and (PARP-2) inhibitors, respectively. In PARP 
enzyme assays using recombinant PARP-1 and PARP-2, quinazolinone derivatives 
displayed relatively high selectivity for PARP-1 and quinoxaline derivatives showed 
superior selectivity for PARP-2. SBDD analysis via a combination of X-ray structural 
study and homology modeling suggested distinct interactions of inhibitors with 
PARP-1 and PARP-2. These findings provide a new structural framework for the 
design of selective inhibitors for PARP-1 and PARP-2.  
 
Where R= H, NH2, Cl, OMe 
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HIV-1 inhibitor 
16) (S) - 4 - isopropoxycarbonyl- 6 - methoxy-3- (methylthiomethyl)-
3,4dihydroquinoxaline-2(1H)-thione (HBY 097) was used to select for drug-resistant 
HIV-1 variants in vitro. The viruses first developed mutations affecting the NNRTI 
binding pocket, and five of six strains displayed the RT G190-E substitution, which is 
characteristic for HIV-1 resistance against quinoxalines.  
 
Structure of (HBY 097) 
 Analgesic and anti-inflammatory activities: 
17)Hashem A., et al., demonstrated analgesic and anti-inflammatory activities of 2-
aminopyrimido [thiazolo[4,5-b]quinoxaline-4-one. Some of these compounds 
exhibited promising activities. 
 
Where, R= F, H, CH3O 
 2-aminopyrimido [thiazolo[4,5-b]quinoxaline-4-one. 
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18)Singh,DharmchandPrasad., et al., Some New Thio-Ether Derivatives of 
Quinoxaline and evaluated for anti-inflammatory activity. The compound substituted 
with cl showed good anti inflammatory 
 
N
N
CH3
S CONH
R
 
2-(2-methylquinoxalin-3-ylthio)-N-substitutedphenyl)acetamides 
R=2-Cl;3-Cl;4-Cl;4-Br;4-CH3 4-OCH3 ;3-Cl 4-F;2-CH3 3-CH3 2-COOCH3 
19) Asuncio ´n Burguete., et al., Synthesized somenew ring substituted 3-phenyl-
1-(1,4-di-N-oxide quinoxalin-2-yl)-2-propen-1-one derivatives and evaluated for anti-
inflammatory activity. The result  showed compound of R=H exhibited good anti -
inflammatory activity 
R N
N
O
O
OH
O-
O-
 
where R=H  R=F  R=CH3O 
20) SMD Noorulla.,et al.,  synthesized some novel substituted quinoxaline 
heterocycle nucleus .The antiinflammatory activity  were conducted . the presence of 
OCH3 on phenyl nucleus attached to second position of the quinoxaline nucleus may 
be responsible for marked anti-inflammatory activity.  
                                                                                                       Literature Review 
 
Dept. of Pharmaceutical Chemistry, MMC, Madurai Page 23 
 
N
N
NH
NH
N
NH O
N
R
 
R= O-OCH3, p- OH, m-NO2, m-OH, P-OCH3 
 
PDGF-R inhibitor 
 21)Myers M., et al., Demonstrated activity novel substituted 2-anilino- and 2-
cycloalkylaminoquinoxalines as inhibitors of PDGF-R autophosphorylation. The 
found that Replacement of an anilino-substituent with substituted cyclohexylamino- 
or norbornylamino substituents lead to significant improvements in the 
pharmacokinetic profile of these analogues.  
 
Where, R1=H, Me, R2= H, Me, R3 and R4= H, Me, MeO 
Antimicrobial activity 
22) Refaat H., et al., were synthesized series of 2-[4-N-2-acylhydrazinocarbonyl) 
aniline]-3-methyl quinoxalines, as well as their cyclized oxadiazolyl derivatives were 
also prepared. Some of these derivatives were evaluated for antimicrobial activity in 
                                                                                                       Literature Review 
 
Dept. of Pharmaceutical Chemistry, MMC, Madurai Page 24 
 
vitro. It was found that all the selected compounds exhibit antimicrobial activity and 
some of these compounds had a broad spectrum of activity.  
 
Where, Ar – 3-Br-C6H4, 4-Br-C6H4, 4-NO2-C6H4 
23) Dharmchand Prasad Singh.,et al., synthesized 2-[4-(substituted-
benziminomethyl)-phenoxy]-3-methyl quinoxalines and 4-(2-methylquinoxalin-3-
yloxy)- N-substituted benzylidine benzamines and evaluated for antimicrobial activity 
. The  compound with 3-OCH3  showed high active against E.coli 
N
N O
N
R
 
R= H; Cl; CH3; 4-COOH; 2- CH3 6- CH3        
N
N O
N
R
 
   R= 4-OH; 2-NO2 ; 4-N(CH3)2 ; 2-OH,3-OCH3 ; 2-OCH3 ,3-OCH3 ,4OCH3 
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24) Shiv Kumar., et al.,  Synthesized  Tetrazolo[1,5-a]quinoxaline based Azetidinones 
& Thiazolidinones  . Some of these derivatives were evaluated for antimicrobial 
activity in vitro. It was found that all the selected compounds exhibit antimicrobial 
activity and some of these compounds had a broad spectrum of activity. 
 
N
N
N
N
NH
NH
N
S
O
R  
R=C6H5, 0-Cl C6H4,O-F C6H4,O-NO2 C6H4,P-ClC6H4,P-F C6H4 ,P-NO2 C6H4 
 
 25) Rantnadee v.ghadge. et al., Synthesized  Schiff’s bases of 3-{[2-({(E) 
-[(substituted) phenyl] methylidene} amino) ethyl] amino}quinoxalin-2(1H)-one  
were evaluated  for  antimicrobial  activity  screening  showed a generally all 
compound are more active against p.aerogenosa  
N
N
H
O
NH
N
Ar
-
 
Ar=3-Cl-C6H5CHO, 3,4,CLC6H3CHO, (CH3)2N-C6H5CHO, OHC12H8CHO 
 26) SMD Noorulla.,et al.,  synthesized some novel substituted quinoxaline 
heterocycle nucleus .The antibacterial tests were conducted on four common 
microorganisms such as Bacillus subtilis, Staphylococcus aureus , Escherichia coli 
and Klebsiella pneumoniae .The synthesized  compound found to be active against 
Bacillus subtilis. 
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N
N
NH
NH
N
NH O
N
R
 
R=p-OCH3, P- OH, m-NO2,m-OH 
Antihistaminic activity 
 27) Sridevi C., et al., synthesized phenyl pyrazolo benzimidazole quinoxaline. 
All the synthesized compounds were screened for their antihistaminic activity.Some 
were shown good % protection of anti-histamic activity.  
 
Anti-proliferativeactivity: 
 28) Chung H., et al., were synthesized a series of 6-arylamino-2,3-bis(pyridin-
2-yl)-7-chloro-quinoxaline-5,8-diones and evaluated for their inhibitory activity on rat 
aortic smooth muscle cell proliferation. They were observed that The quinoxaline-5,8-
diones exhibited a potent anti-proliferative activity.  
 
 6-arylamino-2, 3-bis(pyridin-2-yl)-7-substituted -quinoxaline-5,8-diones 
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                                        Review of reaction 
 
The  various method of preparation of some  substituted quinoxaline-2(1H)-one 
derivative by phillip’s condensation mechanism 
 
I)Condensation of oxalic acid  with o-phenylenediamine 
NH2
NH2
+
OH
OHO
O
stirring,15min
∆ 100 °C
N
H
N
H
O
O
o-phenylene 
diamine oxalic acid
1,4-dihydroquinoxaline-2,3-dione
 
 
2)One-pot efficientgreen synthesis of 1,4-dihydro-quinoxaline-2,3-dione 
                     
+
O OH
OHO
RT
GRINDING
NH2
NH2
N
H
N
H
O
O
A A
B
B
 
 
3)Gris J et al29 has carried out the microwave-assisted Hinsberg reaction of 
quinoxalinone derivatives 
+
O OH
OHR
NH2
NH2
N
H
N
O
R
S. cereviciae
MW Irradiation
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4) Various quinoxaline-2,3-diones32 were synthesized by rotatory  
evaporation of 1,2-diamino aromaticcompounds in diethyl oxalate .           
+
NH
NH2
R
Cl
OH
OH
O
O
R
N
N
H
O
O
Cl
rotavapour
50-80 °C
 
One of the most  features  in quinoxaline-2(1H)-one  chemistry is their use as key 
starting materials for further transformation. The reaction of ethylene diamine  
with quinoxaline-2(1H)-one   results in the formation of 3-[(2-
aminoethyl)amino]quinoxalin-2(1H)-one 
3-[(2-aminoethyl)amino]quinoxalin-2(1H)-one could be used as versatile  building 
blocks in the synthesis of new heterocyclic systems 
Thus the present work is in conjuction  with the reaction of the  amino 
functionality of 3-[(2-aminoethyl)amino]quinoxalin-2(1H)-one with carbon 
electrophiles namely substituted aromatic aldehydes  
 
N
N
H
N H
N H 2
O
N
N
H
N H
N
O
A r
-
ArCHO,EtOH
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The nucleophilic attack of the amino group on the electronically deficient 
carbonyl carbon atom of  the aldehyde , followed by dehydration results in the 
formation of Schiff bases 
As mentioned earlier , 4-Thiazolidinones are reported to possess a variety of 
therapeutic activities. 
Taking in to this consideration .,Cyclocondensation of Schiff's bases with 2-
mercaptopropionic acid afforded 4-thiazolidinone derivatives, 
 
N
N
H
NH
N
O
Ar
-
Thiog lyco lic  ac id ,dm f
zinc  chlor ide
N
N
H
NH
N
O
S
O
Ar
-
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3. SCOPE OF STUDY 
 The aim of the present study was to obtain “Schiff bases quinoxaline 
incorporated with 4-thiazolidinone as biologically effective agent with good 
therapeutic values and minimum toxic levels. 
  From the literature point of view, quinoxaline derivatives display a broad 
spectrum of biological activities. For the development of new therapeutic agents  
it was thought worthwhile to do some chemical modification in quinoxaline 
moieties. In this present study   the effort were made to synthesize.   
a) Schiff  bases of quinoxalinedione derivative 
b) Introducing 4-thiazolidinone nucleus to the Schiff bases 
Our aim in this review is to focus on quinoxaline structure and to analyze 
how slight modification in quinoxaline nucleus can act as a precursor for assembly 
of large number of quinoxaline derivatives and providing a tremendous number of 
pharmacologically active molecules having a wide variety of biological activity 
and also their therapeutic applications and to highlight the importance of 
quinoxaline moiety as a novel drug template for the discovery of new agents in 
various areas of medicines 
 
 
 
 
 
 
 
                                                                                                            Plan of work 
 
Dept. of Pharmaceutical Chemistry,MMC,Madurai                             Page31 
 
PLAN OF WORK 
 
 To design lead molecule of Quinoxaline-2(1H)-one and to assess ADMET  
property. 
 To establish the method of synthesis for the proposed compounds  
 To synthesize the title compounds by appropriate methods  
 To carry out the preliminary tests such as physical constant determination, 
solubility, TLC.  
 To confirm the structures of the synthesized compounds by IR, 
1
H NMR and  
      Mass spectra                                                                                                                                     
 To evaluate the proposed compounds for their in-vitro -anticancer activity , 
               Anti-inflammatory activity and antibacterial activity  
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                                      4. EXPERIMENTAL WORK 
                                          4.1 Molecular design 
      A) OSIRIS PROPERTY EXPLORER 
       It is a software tool  in calculating drug relevant property such as 
Toxicity Risk Assessment 
Mutagenicity ,irritating effect, reproductive effect, tumorigenicity are predicted. 
The prediction process relies on a precomputed set of structural fragment that give 
rise to  toxicity alerts in case they are encountered in the structure currently 
drawn. 
cLogP Prediction: 
1. The logP value of a compound, which is the logarithm of its partition 
coefficient between n-octanol and water log(coctanol/cwater),  
2. It measure of the compound's hydrophilicity. Low hydrophilicities and 
therefore high logP values cause poor absorption or permeation. The value 
must not be greater than 5.0.   
Solubility Prediction: 
1. poor soluble drugs affect absorption and distribution.It is calculated 
interms of  logS value is a unit stripped logarithm (base 10) of the 
solubility measured in mol/liter. logS value greater than -4. 
2. Molecular Weights 
   Most of the trade drug shows molecular weight below 500 
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Drug- Likeness Prediction: 
The druglikeness is calculated with the following equation summing up score 
values of those fragments that are present in the molecule under investigation .The 
value should be positive indicating the fragments predominately present in 
commercial drugs  
Overall Drug- Likeness Score: 
The drug score combines all above parameters to judge the compound's potency. 
The values are 1.0, 0.8 and 0.6 for no risk, medium risk and high risk, respectively 
B) LIPINSKI’S RULE  BY CHEMDOODLE 
Lipinski's Rule of Five is a refinement of drug-likeness and is used to predict 
whether a chemical compound will have pharmacological or biological activity as 
an orally active drug in humans. This rule was formulated by Christopher A. 
Lipinski in 1997, based on the observation that most medication drugs are 
relatively small, lipophilic molecules. 
Lipinski's Rule of Five states that, in general, an orally active drug has: 
1. Not more than 5 hydrogen bond donors (OH and NH groups);  
2. Not more than 10 hydrogen bond acceptors (notably N and O);  
3.A molecular weight under 500 g/mol; and  
4. A partition coefficient log P less than 5 
Note that all numbers are multiples of five, which is the origin of the rule's name. 
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Synthetic compound  were  screened  by using osiris property explorer. 
 Compound1 
 
Compound2 
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Compound3 
 
Compound4 
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compound5 
 
Compound6 
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Compound7 
 
compound8 
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Compound9 
 
compound 10 
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(LIPINSKI’S RULE)ADME property is predicted by Chem.-Doodle software 
Compound 1 
 
                           
Experimental work 
 
Dept. of Pharmaceutical Chemistry, MMC, Madurai Page 40 
 
Compound 2 
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Compound 3 
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Compound 4 
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Compound 5 
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Compound 6 
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Compound 7 
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Compound 8 
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Compound 9 
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Compound 10 
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4.2, SYNTHETIC METHODS 
 
                                              Scheme of synthesis 
 
 
 
NH2
NH2
+
OH
OH
O
O
N
H
N
H
O
O
N
N
H
NH
O
NH2
ETHANOL
stir, 15 min
∆ 100 °C
Reflux for 2 Hrs ethylene diamine
N
N
H
NH
O
N Ar
-
ArCHO
3-[(2-aminoethyl)amino]quinoxalin-2(1H)-one
N
N
H
NH
O
S
N
O
Ar
-
Thioglycolic acid DMF, Zinc chloride
4 -Thiazolidinone carrying substituted 
quinoxalin- 2 one of compound 6-10
Ortho Phenylene diamine
Oxalic acid
1,4-dihydroquinoxaline-2,3-dione
schiff bases of quinoxaline-2-one of 
compound 1-5
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                                  Table1-List of aromatic aldehydes used 
 
Comp.code aldehydes Ar 
1,6 Para methyl benzaldehyde 
4 -CH3C6H4CHO 
 
4 -CH3C6H4 
2,7 Para methoxy benzaldehyde 
4 -OCH3C6H4CHO 
 
4 -OCH3 C6H4 
3,8 Salicylaldehyde 
2 -OHC6H4CHO 
 
2 -OHC6H4 
4,9 Para chloro benzaldehyde 
4 -Cl C6H4CHO 
 
4 -Cl C6H4 
5,10 Benzaldehyde 
C6H5CHO 
 
C6H5 
 
   GENERAL PROCEDURE 
    STEP1: 
Synthesis  of 1,4-dihydroquinoxaline-2,3-dione 
NH2
NH2
+
OH
OH
O
O
N
H
N
H
O
O
stir, 15 min
∆ 100 °C
Ortho Phenylene diamine
Oxalic acid
1,4-dihydroquinoxaline-2,3-dione
 
A solution of oxalic acid dehydrate (0.238mole, 30g) in water (100ml) was heated to      
100 °C and conc. HCl 45ml  was added, followed by O-phenylendiamine (0.204 
mole, 22g) with stirring, temperature was maintained at 100 °C for 20 min. The 
mixture cooled by addition of ice. The precipitate was formed and washed with water. 
Product was recrystallized form  ethanol. 
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STEP 2:  
Synthesis of 3-[(2-aminoethyl)amino]-3,4- dihydroquinoxalin-2(1H)-one 
N
H
N
H
O
O N
N
H
NH
O
NH2
Ethylene diamine
Reflux 2 Hrs
1,4-dihydroquinoxaline-2,3-dione
3-[(2-aminoethyl)amino]quinoxalin-2(1H)-one
 
A mixture of the quinoxalindione (l) (0.062 mole, 10.04g), ethylene diamine (1mole, 
50ml,) and water (50ml) was heated under reflux for 2hrs, then cooled to room 
temperature, the precipitate was filtered, washed with water and crystallized from 2-
butanol. 
PREPARATION OF SCHIFF’S BASES OF QUINOXALINES OF 
COMPOUND 1 TO COMPOUND5: 
Synthesis of compound 1: 
N
N
H
NH
O
NH2
3-[(2-aminoethyl)amino]quinoxalin
-2(1H)-one
N
N
H
NH
O
N
CH3
3-({2-[(E)-(4-methylbenzylidene)amin
o]ethyl}amino)quinoxalin-2(1H)-one
para methyl benzaldehyde
ethanol
 
In this step, compound 3-[(2 amino ethyl) amino] quinoxalin-2(1H) – one and 
para methyl benzadehyde (0.01mole of each) in ethanol as solvent (20ml) was 
refluxed for 5hr. Upon cooling the precipitate was obtained, filtered, dried and 
crystallized from ethanol. 
Synthesis of compound 2: 
N
N
H
NH
O
NH2
3-[(2-aminoethyl)amino]quinoxalin
-2(1H)-one
N
N
H
NH
O
N
OCH3
para methoxy benzaldehyde
ethanol
3-({2-[(E)-(4-methoxybenzylidene)amino]
ethyl}amino)quinoxalin-2(1H)-one
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In this step, compound 3-[(2 amino ethyl) amino] quinoxalin-2(1H) – one and para 
methoxy benzadehyde (0.01mole of each) in ethanol as solvent (20ml) was refluxed 
for 5hr. Upon cooling the precipitate was obtained, filtered, dried and crystallized 
from ethanol. 
Synthesis of compound 3: 
N
N
H
NH
O
NH
2
3-[(2-aminoethyl)amino]quinoxalin
-2(1H)-one
N
N
H
NH
O
N
OH
3-({2-[(E)-(2-hydroxybenzylidene)amino]
ethyl}amino)quinoxalin-2(1H)-one
salicylaldehyde
ethanol
 
In this step, compound 3-[(2 amino ethyl) amino] quinoxalin-2(1H) – one and 2- 
hydroxy benzadehyde (0.01mole of each) in ethanol as solvent (20ml) was refluxed 
for 5hr. Upon cooling the precipitate was obtained, filtered, dried and crystallized 
from ethanol. 
Synthesis of compound 4:  
 
N
N
H
NH
O
NH2
3-[(2-aminoethyl)amino]quinoxalin
-2(1H)-one
N
N
H
NH
O
N
Cl
3-({2-[(E)-(4-chlorobenzylidene)amino
]ethyl}amino)quinoxalin-2(1H)-one
para chloro benzaldehyde
ethanol
 
 
In this step, compound 3-[(2 amino ethyl) amino] quinoxalin-2(1H) – one and para 
chloro benzadehyde (0.01mole of each) in ethanol as solvent (20ml) was refluxed for 
5hr. Upon cooling the precipitate was obtained, filtered, dried and crystallized from 
ethanol. 
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synthesis of compound 5: 
N
N
H
NH
O
NH2
3-[(2-aminoethyl)amino]quinoxalin
-2(1H)-one
N
N
H
NH
O
N
3-({2-[(E)-benzylideneamino]ethyl}amin
o)quinoxalin-2(1H)-one
 benzaldehyde
ethanol
 
In this step, compound 3-[(2 amino ethyl) amino] quinoxalin-2(1H) – one and 
benzadehyde (0.01mole of each) in ethanol as solvent (20ml) was refluxed for 5hr. 
Upon cooling the precipitate was obtained, filtered, dried and crystallized from 
ethanol. 
Synthesis of quinoxaline based 4-thiazolidinone(compound6-compound10) from 
Schiff bases of compound(1-5) 
 Synthesis of compound6: 
N
N
H
NH
O
N
CH
3
N
N
H
NH
O
S
N
O
CH
3
3-({2-[2-(4-methylphenyl)-4-oxo-1,3-thiazolidin-3-yl]eth
yl}amino)quinoxalin-2(1H)-one
Thioglycolic acid,dmf
zinc chloride(catalyst)
3-({2-[(E)-(4-methylbenzylidene)amino]ethyl}a
mino)quinoxalin-2(1H)-one
 
A mixture of 3-(p-methyl benzylidene ethylenediamino) quinoxaline-2-(1H)- 
one(compound 1, 0.01mol) and thioglycolic acid (0.01mol) in 30ml of DMF in the 
presence of catalytic amount of anhydrous zinc chloride and was refluxed in sand bath 
for about 10hrs. The residue was washed with sodium bicarbonate solution and the 
product was washed with water thoroughly and crystallized from alcohol to get solid 
crystals.   
 
 
 
                                                                                                   Experimental work                              
 
Dept. of Pharmaceutical Chemistry, MMC, Madurai Page 54 
 
Synthesis of compound 7: 
N
N
H
NH
O
N
OCH3
Thioglycolic acid,dmf
zinc chloride(catalyst)
N
N
H
NH
O
S
N
O
OCH3
3-({2-[(E)-(4-methoxybenzylidene)amino
]ethyl}amino)quinoxalin-2(1H)-one
3-({2-[2-(4-methoxyphenyl)-4-oxo-1,
3-thiazolidin-3-yl]ethyl}amino)quin
oxalin-2(1H)-one
 
A mixture of 3-(p-methoxyy benzylidene ethylenediamino) quinoxaline-2-(1H)- one 
(compound 2, 0.01mol) and thioglycolic acid (0.01mol) in 30ml of DMF in the 
presence of catalytic amount of anhydrous zinc chloride and was refluxed in sand bath 
for about 10hrs. The residue was washed with sodium bicarbonate solution and the 
product was washed with water thoroughly and crystallized from alcohol to get solid 
crystals.   
Synthesis of compound 8: 
N
N
H
NH
O
N
OH
3-({2-[(E)-(2-hydroxybenzylidene)amino]
ethyl}amino)quinoxalin-2(1H)-one
N
N
H
NH
O
S
N
O
OH
3-({2-[2-(2-hydroxyphenyl)-4-oxo-1,3-
thiazolidin-3-yl]ethyl}amino)quinoxal
in-2(1H)-one
thioglycolic acid,DMF
zinc chloride
 
A mixture of 3-(2-OH benzylidene ethylenediamino) quinoxaline-2-(1H)- 
one(compound 3, 0.01mol) and thioglycolic acid (0.01mol) in 30ml of DMF in the 
presence of catalytic amount of anhydrous zinc chloride and was refluxed in sand bath 
for about 10hrs. The residue was washed with sodium bicarbonate solution and the 
product was washed with water thoroughly and crystallized from alcohol to get solid 
crystals.   
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Synthesis of compound 9: 
N
N
H
NH
O
N
Cl
3-({2-[(E)-(4-chlorobenzylidene)amino
]ethyl}amino)quinoxalin-2(1H)-one
Thioglycolic acid,dmf
zinc chloride(catalyst)
N
N
H
NH
O
S
O
N
Cl
3-({2-[2-(4-chlorophenyl)-4-oxo-1,3-thiazolidin-3-yl
]ethyl}amino)quinoxalin-2(1H)-one
 
A mixture of 3-(p-cl benzylidene ethylenediamino)quinoxaline-2-(1H)-one(compound 
4, 0.01mol) and thioglycolic acid (0.01mol) in 30ml of DMF in the presence of 
catalytic amount of anhydrous zinc chloride and was refluxed in sand bath for about 
10hrs. The residue was washed with sodium bicarbonate solution and the product was 
washed with water thoroughly and crystallized from alcohol to get solid crystals.  
Synthesis of compound 10: 
Thioglycolic acid,dmf
zinc chloride(catalyst)
N
N
H
NH
O
N
3-({2-[(E)-benzylideneamino]ethyl}amin
o)quinoxalin-2(1H)-one
N
N
H
NH
O
S
N
O
3-{[2-(4-oxo-2-phenyl-1,3-thiazolidin-3-yl)ethyl]
amino}quinoxalin-2(1H)-one
A mixture of 3-(benzylidene ethylenediamino) quinoxaline-2-(1H)- one (compound 5, 
0.01mol) and thioglycolic acid (0.01mol) in 30ml of DMF in the presence of catalytic 
amount of anhydrous zinc chloride and was refluxed in sand bath for about 10hrs. The 
residue was washed with sodium bicarbonate solution and the product was washed 
with water thoroughly and crystallized from alcohol to get solid crystals.   
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                                4.3 ANALYTICAL TECHNIQUES 
Physical Data: 
Melting point was found in an open end capillary tube method by electrically  heating  
melting point apparatus. 
 Thin Layer Chromatography (TLC): 
Thin layer chromatographic analysis  was carried out by using silica gel (0.5mm 
thickness) coated over glass plate (12x20cm)as stationary phase. Ethyl acetate: n-
Hexane(1:1)  as mobile phase, the spots were visualized by iodine vapours.   
Instrumentation: 
The techniques employed for the characterization of the synthesized compounds were 
IR spectra, 
1
H-NMR spectra, Mass spectra. 
Infrared Spectra: 
The IR spectra of the synthesized compounds were recorded on a Fourier Transform 
IR spectrometer (Perkin-Elmer) in the range of 4000 – 450 cm
-1
 Nujol mull technique 
and the values are reported. 
Nuclear Magnetic Resonance Spectra (
1
H-NMR): 
        1
H-NMR spectra were recorded on Bruker – NMR 400 MHz using DMSO  
     and    chemical shifts were reported in parts per million (δ ppm)                                    
 Mass spectroscopy: 
    Mass spectra were recorded on   Mass Spectroscopy JEOL GC mate 
    and   molecular ion peak are recorded in m/z ratio.               
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                             4.4 Evaluation of biological activity 
a) IN -VITRO ANTICANCER ACTIVITY 
Introduction 
The cytotoxicity of  Quinoxaline 2-one derivative was evaluated by MTT assay 
(Microculture tetrazolium assay).   The percentage growth inhibition was calculated 
by measuring   the absorbance using microplate reader at a wavelength of 570nm. 
Principle 
 MTT is a yellow water soluble substrate 3-(4,5-dimethyl thiazol-2-yl)-2,5-
diphenyl tetrazolium bromide salt. A mitochondrial enzyme in living cells, succinate-
dehydrogenase, cleaves the tetrazolium ring, converting the MTT to an insoluble 
purple formazan. Therefore, the amount of formazan produced is directly proportional 
to the number of viable cells. 
Materials and  method 
Cell line used 
The human colorectal carcinoma cell line (HCT116) was obtained from 
National Centre for Cell Science (NCCS), Pune, 
Media 
     Dulbeccos Modified Eagles Medium (DMEM) containing 10% fetal bovine serum  
(FBS).  
     Equipments 
96-well micro titre plate,tissue culture flask,co2 incubator 
Cell treatment procedure 
 All cells were grown in DMEM and maintained at 37
0
C, 5% CO2, 95% air and 
100% relative humidity. Maintenance cultures were passaged weekly, and the culture 
medium was changed twice a week. The monolayer cells were detached with trypsin-
ethylenediaminetetraacetic acid (EDTA) to make single cell suspensions and viable 
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cells were counted using a hemocytometer and diluted with medium with 5% FBS to 
give final density of 1x10
5
 cells/ml. one hundred microlitres per well of cell 
suspension were seeded into 96-well plates at plating density of 10,000 cells/well and 
incubated to allow for cell attachment at 37
0
C, 5% CO2, 95% air and 100% relative 
humidity. After 24 h the cells were treated with serial concentrations of the extracts 
and fractions. They were initially dissolved in neat dimethylsulfoxide (DMSO) and 
further diluted in serum free medium to produce five concentrations. One hundred 
microlitres per well of each concentration was added to plates to obtain final 
concentrations of 100, 10, 1.0 and 0.1 µM. The final volume in each well was 200 µl 
and the plates were incubated at 37
0
C, 5% CO2, 95% air and 100% relative humidity 
for 48h. The medium containing without samples were served as control. Triplicate 
was maintained for all concentrations. 
 After 48h of incubation, 15µl of MTT (5mg/ml) in phosphate buffered saline 
(PBS) was added to each well and incubated at 37
0
C for 4h. The medium with MTT 
was then flicked off and the formed formazan crystals were solubilized in 100µl of 
DMSO and then measured the absorbance at 570 nm using micro plate reader. The % 
cell inhibition was determined using the following formula.  
% cell Inhibition = 100- Abs (sample)/Abs (control) x100.  
Nonlinear regression graph was plotted between % Cell inhibition and Log10 
concentration and  IC50 was determined using Graph Pad Prism software. 
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B ) IN-VITRO ANTI-INFLAMMATORY ACTIVITY 
 Introduction 
A number of anti-inflammatory drugs are known to inhibit the denaturation of 
proteins as an invitro screening model for anti-inflammatory compounds. The 
synthesized compounds were screened for anti-inflammatory activity by using 
inhibition of albumin denaturation technique. 
Materials and  method 
Equipment 
BOD incubator,uv spectrophotometer and thermostatically controlled water bath 
Media 
Bovine serum albumin 
Reagent  
Phosphate buffer -0.2M, pH7.4 
Drugs 
Standard drug   :  different   concentration of   Ibuprofen 
Test drug          :  different   concentration  of  compound1-10 
Procedure 
              The standard drug and test compounds were dissolved in minimum amount 
of dimethyl formamide (DMF) and diluted with phosphate buffer (0.2 M, pH 7.4). 
Final concentration of DMF in all solutions was less than 2.0%. Test solution (1 ml) 
containing different concentrations of drug was mixed with 1 ml of   1mM albumin 
solution in phosphate buffer and incubated at 27°±1°C in BOD incubator for 15 min. 
Denaturation was induced by keeping the reaction mixture at 60°±1°C in water bath 
for 10 min. After cooling the turbidity was measured at 660 nm (UV-Visible 
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Spectrophotometer.). Percentage of inhibition of denaturation was calculated from 
control where no drug was added. Each experiment was done in triplicate and average 
was taken 
                % Inhibition of denaturation= [(Vt/Vc)-1] × 100 
                             Where, Vt   = mean absorption of   test compound, 
                                  Vc =   mean absorption of control 
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C). In-vitro evaluation of antibacterial activity 
Introduction 
   The invitro antibacterial activity  can be evaluated by a)  Agar streak dilution  
method b)  Serial dilution method c) Agar diffusion method(Cup plate method, 
Cylinder method, Paper disc method )d)  Turbidimetry method .Among this diffusion 
techniques are widely used to carry out sensitivity test for pathogenic microorganism 
.It was evaluated by measuring the zone of inhibition in mm  
 Materials and  method 
Equipments 
     Sterile petriplates ,sterile forceps and loop, whatmannno.1 filter paper 
medium 
muller hinton agar medium 
Organisms Used: 
Gram Positive Organisam:  
Staphylococcus aureus 
Gram Negative Organisam 
Escherichia coli 
Klebsiella pneumonae 
 Pseudomonas aureginosa                 
Proteus mirabilis 
  
The antibacterial activities of the synthesized compounds were studied by disc 
diffusion method. All the compounds were used in the concentration of  150 µg/ disc 
using a solvent DMSO. Ciprofloxacin 30 µg/ disc was used as standard 
Preparation of Muller Hinton Agar 
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   Composition of muller Hinton agar 
• Beef Extract                         -10gms 
• Casein acid hydrosylate       -  17.5gms 
• Starch                                   -1.5gms 
• Agar                                      - 20gms 
• Distilled water                       -1000ml 
        
     Procedure:  
The above mentioned ingredients were dissolved with help of heat. It was 
filtered and sterilized by maintaining at 121
o
C for 20 minutes in autoclave and 
adjusted the pH to 7.3 ± 0.1 
Method: 
Disc diffusion Method: 
A suspension of the organism was added to sterile nutrient agar medium at 
45
o
C. The mixture was transferred to sterile petridishes and allowed to solidify. 
Sterile disc 5 mm in diameter (made from Whatmann filter paper which is 
previously sterilized in UV lamp now commercially also available) was dipped in 
solution of different concentrations of compound for around 1 h, standard and a 
blank were placed on the surface of agar plates. 
Left the plates to stand for 1 h at room temperature as a period of 
preincubation to minimize the effects of variation in time between the applications 
of the different solutions. Then the plate were incubated for 24 h at 37 ± 1
o
C and 
observed for antibacterial activity. The diameter of zone of inhibition was 
observed  
In this method 
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a) The inoculums was adjusted to give uniform dense 
b) A standard sensitivity medium was used 
c) Disc containing suitable known amounts of drug should be stable on storage 
and reproducible results were obtained between batches 
d) The conditions of incubation and other factors also must be standardized as 
well as the method of interpreting the inhibition zone around discs. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Results  
&  
Discussion 
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                                       5. Results & Discussion 
 Characterization  of synthezised compound 
Table2-Structure and IUPAC name of the newly synthesized compounds  
Comp 
code 
structure and chemical name 
1 
N
N
H
O
NH
N
3-({2-[(4-methylbenzylidene)amino]ethyl}amino)quinoxalin-
2(1H )-one
 
2 
N
N
H
O
NH
N
O
3-({2-[(4-methoxybenzylidene)amino]ethyl}amino)quinoxalin-2(1H)-one
 
3 
N
N
H
O
NH
N
OH
3-({2-[(2-hydroxybenzylidene)amino]ethyl}amino)quinoxalin-
2(1H)-one
 
4 
N
N
H
O
NH
N
Cl
3-({2-[(4-chlorobenzylidene)amino]ethyl}amino)quinoxalin-
2(1H )-one
 
5 
N
N
H
O
NH
N
3 -({2 -[benzylideneam ino]ethyl}am ino)qu inoxalin-
2 (1H )-one
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6 
N
N
H
O
NH
N
S
O
3-({2-[2-(4-methylphenyl)-4-oxo-1,3-thiazolidin-3-yl]
ethyl}amino)quinoxalin-2(1H )-one
 
 
7 
N
N
H
O
NH
N
S
O
O
3-({2-[2-(4-methoxyphenyl)-4-oxo-1,3-thiazolidin-3-yl]ethyl}
amino)quinoxalin-2(1H)-one
 
 
8 
N
N
H
O
NH
N
S
O
OH
3-({2-[2-(2-hydroxyphenyl)-4-oxo-1,3-thiazolidin-3-yl]ethyl}amino)
quinoxalin-2(1H )-one
 
 
9 
N
N
H
O
N H
N
S
O
C l
3 -({ 2 -[2 -(4 -ch lo ropheny l)-4 -oxo -1 ,3 -th ia zo lid in -3 -y l]e thy l} a m ino )
qu inoxa lin -2 (1H ) -one
 
 
10 
N
N
H
O
NH
N
S
O
3-{[2-(4-oxo-2-phenyl-1,3-thiazolidin-3-yl)ethyl]amino}quinoxalin-
2(1H)-one
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                              5.1 PHYSICAL CHARACTERIZATION 
Table3-Physical Data of the Synthesized Compounds 
comp m.f m.w m.p Rf % solubility Appearance/color 
code (°c) yield 
1 C18H18N4O 306.3 212 0.76 58 DMSO Solid/white 
2 C18H18N4O2 322.3 190 0.82 61 DMSO Solid/white 
3 C17H16N4O2 308.3 222 0.76 60 DMSO Solid/yellow 
4 C17H15ON4Cl 326.7 300 0.85 62 DMSO Solid/white 
5 C17H16N4O 292.3 230 0.82 71 DMSO Solid/white 
6 C20H20N4O2S 380.4 157 0.66 58 DMSO Solid/buff 
7 C20H20N4O3S 396.4 177 0.78 60 DMSO Solid/yellow 
8 C19H18N4O3S 382.4 182 0.82 62 DMSO Solid/pale yellow 
9 C19H17 
N4O2SCl 
400.8 122 0.71 56 DMSO Solid/pale yellow 
10 C19H18N4O2S 366.4 156 0.8 77 DMSO Solid/yellow 
 
Table4-- Elemental analysis of synthesized compound 
Elemental analysis 
comp 
code 
%C %H %N %O %S %Cl 
1 70.57 5.92 18.29 5.22 - - 
2 67.07 5.63 17..38 9.93 - - 
3 66.22 5.23 18.17 10.38 - - 
4 62.48 4.63 17.15 4.9 - 10.85 
5 69.85 5.52 19.17 5.47 - - 
6 63.14 5.3 14.73 8.41 8.43 - 
7 60.59 5.08 14.13 12.11 8.09 - 
8 59.67 4.74 14.65 12.55 8.38 - 
9 56.93 4.27 13.98 7.98 8 8.84 
10 62.28 4.95 15.29 8.73 8.75 - 
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                    5.2 RESULTS OF MOLECULAR DESIGN 
 
 
Table5 – Drug relevant property by using OSIRIS property Explorer  
 The toxicity of synthesized compound are under safety margin ,which shows green in  
 Osiris property explorer 
 
 
Table6--Lipinski rule of synthesized compound using   Chemdoodle  software 
Comp M. 
W 
Log 
P 
H 
bond 
donor 
H bond 
acceptor 
Mol. 
refractivit
y 
Number 
of 
criteria 
met 
rule < 
500 
<5 <5 <10 40-130 At least 
3 
      1 306.3 1.4 2 3 92.459 All 
2 322.3 0.08 2 4 93.990   All 
3 308.3 0.78 3 4 89.352 All 
4 326.7 1.00 2 3 92.735 All 
5 292.3 1.08 2 3 87.821 All 
6 380.4 1.43 2 4 108.635 All 
7 396.5 1.01 2 5 110.166 All 
8 382.4 0.82 3 5 105.528 All 
9 400.8 1.73 2 4 108.911 All 
10 366.4 1.12 2 4 103.997 All 
 
 
 
Comp 
      Code 
 
Drug-likeness Drug score 
1 3.57 0.84 
2 5.11 0.87 
3 4.94 0.89 
4 5.78 0.81 
5 4.94 0.88 
6 5.27 0.83 
7 6.8 0.84 
8 6.62 0.80 
9 7.37 0.70 
10 6.59 0.86 
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                                          5.3 SPECTRAL ANALYSIS 
  Table 7-IR studies of synthesized compound  
Compound code Spectral peaks(cm-1) Molecular nature 
1                         3048.04 
1683.63 
1500.69 
1474.05 
1419.05 
819.81 
Ar. C – H Stretching 
C=0 Stretching 
C=C Stretching(aromatics) 
CH=N Stretching 
C-H def (in CH3) 
P- substituted Benzene 
2 3317.91 
3016.12 
1677.58 
1511.97 
1465.55 
1312.20 
1021.65 
                N – H Stretching 
Ar. C – H Stretching 
C=0 Stretching 
C=C Stretching(aromatics) 
CH=N Stretching 
C-O stretching (phenol) 
C-O-C Stretching 
3 3317.91 
2920.61 
1677.58 
1511.97 
1465.55 
1248.13 
N – H Stretching 
OH Stretching 
C=O Stretching 
C=CStretching(aromatics) 
CH=N Stretching 
C-N  Stretching 
4 3049.73 
1681.75 
1419.77 
1500.92 
1248.32 
759.40 
Ar. C – H Stretching 
C=O Stretching 
CH=N Stretching   
C=CStretching(aromatics) 
C-NStretching 
C-Cl 
5 3317.70 
3015.93 
1677.01 
1464.28 
1512.23 
1247.79 
N – H Stretching 
Ar. C – H Stretching 
C=0 Stretching 
CH=N Stretching 
C=CStretching(aromatics) 
C-NStretching 
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Compound code Spectral peaks(cm-1)  Molecular nature 
6 3048.23 
2968.95 
1683.97 
1500.87 
1473.56 
1419.81 
1247.69 
Ar. C – H Stretching 
CH Stretching OF CH3 
C=0 Stretching 
C=CStretching(aromatics) 
CH=N Stretching 
CH2-S- 
C-N Stretching 
7 3395.94 
3048.51 
2968.34 
1683.35 
1510.58 
1419.90 
1249.44 
1030.71 
854.81 
N – H Stretching 
CAr. C – H Stretching 
CH Stretching OF CH3 
C=0 Stretching 
C=CStretching(aromatics 
CH2-S- 
C-N Stretching 
C-O-C Stretching 
P- substituted Benzenes 
8 3159.92 
3049.30 
1683.42 
1501.12 
1419.88 
1473.71 
                       1248.07                 
OH Stretching 
Ar. C – H Stretching 
C=0 Stretching 
C=CStretching(aromatics 
CH2-S- 
CH=N Stretching 
C-N Stretching 
9 3411.44 
3022.06 
1685.31 
1488.77 
1264.79 
743.58 
N – H Stretching 
Ar. C – H Stretching 
C=0 Stretching 
CH2-S- 
C-N Stretching 
                 C-Cl 
10 3421.79 
3050.74 
1683.36 
1501.73 
1474.20 
1420.09 
1248.48 
N – H Stretching 
Ar. C – H Stretching 
C=0 Stretching 
C=CStretching(aromatics 
CH=N Stretching 
CH2-S- 
C-N Stretching 
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Compound 1 
 
Compound 2 
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Compound 3 
       
 Compound4   
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Compound 5 
 
Compound 6 
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Compound 7 
 
Compound 8 
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   Compound 9 
 
Compound 10 
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Table8- NMR studies of synthesized compound 
Compound code  Chemical shift Proton nature 
1 7.9678 
7.2963 
6.8103 
9.9735 
3.7332 
8.5615 
2.6825 
t,2H,Ar-H 
d,2H,Ar-H 
d,5H,Ar-H 
s,1H,CH=N 
s,1H,NH 
s,1H,NHCO 
t,2H,CH2 
2 7.9225 
7.2035 
4.05097 
7.2891 
2.6276 
2.3235 
t,2H,Ar-H 
d,2H,Ar-H 
s,1H,NH 
s,1H,NHCO 
t,2H,CH2 
s,3H,OCH3 
3 7.9427 
7.2964 
6.8693 
3.7933 
9.0258 
8.1497 
2.5907 
t,2H,Ar-H 
d,2H,Ar-H 
d,5H,Ar-H 
s,1H,NH 
s,1H,CH=N 
s,1H,NHCO 
t,2H,CH2 
4 7.2474 
6.9905 
4.0812 
7.5861 
2.6754 
d,2H,Ar-H 
d,5H,Ar-H 
s,1H,NH 
s,1H,NHCO 
t,2H,CH2 
5 7.2679 
6.7634 
4.1300 
7.1783 
3.8403 
d,2H,Ar-H 
d,5H,Ar-H 
s,1H,NH 
s,1H,NHCO 
t,2H,CH2 
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Compound code  Chemical shift Proton nature 
6 7.4731 
7.2181 
6.2307 
9.0745 
3.5515 
8.0772 
2.6012 
t,2H,Ar-H 
d,2H,Ar-H 
d,5H,Ar-H 
s,1H,CH=N 
s,1H,NH 
s,1H,NHCO 
t,2H,CH2 
7 7.5473 
7.2132 
3.9650 
2.5103 
2.3652 
t,2H,Ar-H 
d,2H,Ar-H 
s,1H,NH 
t,2H,CH2 
s,3H,OCH3 
8 7.5473 
7.2676 
6.7663 
9.1853 
3.9803 
8.0099 
2.5959 
t,2H,Ar-H 
d,2H,Ar-H 
d,5H,Ar-H 
s,1H,CH=N 
s,1H,NH 
s,1H,NHCO 
t,2H,CH2 
9 
 
 
 
 
 
 
7.2656 
6.7543 
3.9324 
8.4251 
2.5995 
d,2H,Ar-H 
d,5H,Ar-H 
s,1H,NH 
s,1H,NHCO 
t,2H,CH2 
10 7.5363 
7.2723 
6.8350 
3.9353 
8.6903 
2.5984 
t,2H,Ar-H 
d,2H,Ar-H 
d,5H,Ar-H 
s,1H,NH 
s,1H,NHCO 
t,2H,CH2 
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Compound 2 
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NS                    8
DS                    2
SWH           12019.230 Hz
FIDRES         0.183399 Hz
AQ            2.7263477 sec
RG                  228
DW               41.600 usec
DE                 6.00 usec
TE                292.7 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                10.90 usec
PL1               -3.00 dB
SFO1        400.1324710 MHz
F2 - Processing parameters
SI                32768
SF          400.1300081 MHz
WDW                  EM
SSB                   0
LB                 0.30 Hz
GB                    0
PC                 1.00
PARVATHI-2
BRUKER
AVANCE II 400 NMR
Spectrometer
SAIF
Panjab University
Chandigarh
avtar_saifpu@yahoo.co.in  
0.60.81.01.21.41.61.82.02.22.42.62.83.03.2 ppm
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SOLVENT           CDCl3
NS                    8
DS                    2
SWH           12019.230 Hz
FIDRES         0.183399 Hz
AQ            2.7263477 sec
RG                  228
DW               41.600 usec
DE                 6.00 usec
TE                292.7 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                10.90 usec
PL1               -3.00 dB
SFO1        400.1324710 MHz
F2 - Processing parameters
SI                32768
SF          400.1300081 MHz
WDW                  EM
SSB                   0
LB                 0.30 Hz
GB                    0
PC                 1.00
PARVATHI-2
BRUKER
AVANCE II 400 NMR
Spectrometer
SAIF
Panjab University
Chandigarh
avtar_saifpu@yahoo.co.in  
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Compound 3 
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NAME         Jan13-2012
EXPNO               130
PROCNO                1
F2 - Acquisition Parameters
Date_          20120113
Time              14.18
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG            zg30
TD                65536
SOLVENT            DMSO
NS                    8
DS                    2
SWH           12019.230 Hz
FIDRES         0.183399 Hz
AQ            2.7263477 sec
RG                  181
DW               41.600 usec
DE                 6.00 usec
TE                292.7 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                10.90 usec
PL1               -3.00 dB
SFO1        400.1324710 MHz
F2 - Processing parameters
SI                32768
SF          400.1300000 MHz
WDW                  EM
SSB                   0
LB                 0.30 Hz
GB                    0
PC                 1.00
PARVATHI-3
BRUKER
AVANCE II 400 NMR
Spectrometer
SAIF
Panjab University
Chandigarh
avtar_saifpu@yahoo.co.in  
 
 
6.36.46.56.66.76.86.97.07.17.27.37.47.57.67.77.87.98.08.18.2 ppm
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Current Data Parameters
NAME         Jan13-2012
EXPNO               130
PROCNO                1
F2 - Acquisition Parameters
Date_          20120113
Time              14.18
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG            zg30
TD                65536
SOLVENT            DMSO
NS                    8
DS                    2
SWH           12019.230 Hz
FIDRES         0.183399 Hz
AQ            2.7263477 sec
RG                  181
DW               41.600 usec
DE                 6.00 usec
TE                292.7 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                10.90 usec
PL1               -3.00 dB
SFO1        400.1324710 MHz
F2 - Processing parameters
SI                32768
SF          400.1300000 MHz
WDW                  EM
SSB                   0
LB                 0.30 Hz
GB                    0
PC                 1.00
PARVATHI-3
BRUKER
AVANCE II 400 NMR
Spectrometer
SAIF
Panjab University
Chandigarh
avtar_saifpu@yahoo.co.in  
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Compound 4 
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NAME         Jan13-2012
EXPNO               140
PROCNO                1
F2 - Acquisition Parameters
Date_          20120113
Time              14.23
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG            zg30
TD                65536
SOLVENT            DMSO
NS                    8
DS                    2
SWH           12019.230 Hz
FIDRES         0.183399 Hz
AQ            2.7263477 sec
RG                   57
DW               41.600 usec
DE                 6.00 usec
TE                292.8 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                10.90 usec
PL1               -3.00 dB
SFO1        400.1324710 MHz
F2 - Processing parameters
SI                32768
SF          400.1281138 MHz
WDW                  EM
SSB                   0
LB                 0.30 Hz
GB                    0
PC                 1.00
PARVATHI-4
BRUKER
AVANCE II 400 NMR
Spectrometer
SAIF
Panjab University
Chandigarh
avtar_saifpu@yahoo.co.in  
1.21.31.41.51.61.71.81.92.02.12.22.32.42.52.62.72.82.9 ppm
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F2 - Acquisition Parameters
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TD                65536
SOLVENT            DMSO
NS                    8
DS                    2
SWH           12019.230 Hz
FIDRES         0.183399 Hz
AQ            2.7263477 sec
RG                   57
DW               41.600 usec
DE                 6.00 usec
TE                292.8 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                10.90 usec
PL1               -3.00 dB
SFO1        400.1324710 MHz
F2 - Processing parameters
SI                32768
SF          400.1281138 MHz
WDW                  EM
SSB                   0
LB                 0.30 Hz
GB                    0
PC                 1.00
PARVATHI-4
BRUKER
AVANCE II 400 NMR
Spectrometer
SAIF
Panjab University
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Compound 5 
11 10 9 8 7 6 5 4 3 2 1 0 ppm
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NAME         Jan13-2012
EXPNO               150
PROCNO                1
F2 - Acquisition Parameters
Date_          20120113
Time              14.29
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG            zg30
TD                65536
SOLVENT           CDCl3
NS                    8
DS                    2
SWH           12019.230 Hz
FIDRES         0.183399 Hz
AQ            2.7263477 sec
RG                 71.8
DW               41.600 usec
DE                 6.00 usec
TE                292.8 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                10.90 usec
PL1               -3.00 dB
SFO1        400.1324710 MHz
F2 - Processing parameters
SI                32768
SF          400.1300063 MHz
WDW                  EM
SSB                   0
LB                 0.30 Hz
GB                    0
PC                 1.00
PARVATHI-5
BRUKER
AVANCE II 400 NMR
Spectrometer
SAIF
Panjab University
Chandigarh
avtar_saifpu@yahoo.co.in  
5.86.06.26.46.66.87.07.27.47.67.88.0 ppm
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NAME         Jan13-2012
EXPNO               150
PROCNO                1
F2 - Acquisition Parameters
Date_          20120113
Time              14.29
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG            zg30
TD                65536
SOLVENT           CDCl3
NS                    8
DS                    2
SWH           12019.230 Hz
FIDRES         0.183399 Hz
AQ            2.7263477 sec
RG                 71.8
DW               41.600 usec
DE                 6.00 usec
TE                292.8 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                10.90 usec
PL1               -3.00 dB
SFO1        400.1324710 MHz
F2 - Processing parameters
SI                32768
SF          400.1300063 MHz
WDW                  EM
SSB                   0
LB                 0.30 Hz
GB                    0
PC                 1.00
PARVATHI-5
BRUKER
AVANCE II 400 NMR
Spectrometer
SAIF
Panjab University
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Compound 6 
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NAME         Jan13-2012
EXPNO               160
PROCNO                1
F2 - Acquisition Parameters
Date_          20120113
Time              14.35
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG            zg30
TD                65536
SOLVENT            DMSO
NS                    8
DS                    2
SWH           12019.230 Hz
FIDRES         0.183399 Hz
AQ            2.7263477 sec
RG                  114
DW               41.600 usec
DE                 6.00 usec
TE                292.8 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                10.90 usec
PL1               -3.00 dB
SFO1        400.1324710 MHz
F2 - Processing parameters
SI                32768
SF          400.1299779 MHz
WDW                  EM
SSB                   0
LB                 0.30 Hz
GB                    0
PC                 1.00
PARVATHI-6
BRUKER
AVANCE II 400 NMR
Spectrometer
SAIF
Panjab University
Chandigarh
avtar_saifpu@yahoo.co.in  
1.01.11.21.31.41.51.61.71.81.92.02.12.22.32.42.52.62.72.82.9 ppm
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F2 - Acquisition Parameters
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TD                65536
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DS                    2
SWH           12019.230 Hz
FIDRES         0.183399 Hz
AQ            2.7263477 sec
RG                  114
DW               41.600 usec
DE                 6.00 usec
TE                292.8 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                10.90 usec
PL1               -3.00 dB
SFO1        400.1324710 MHz
F2 - Processing parameters
SI                32768
SF          400.1299779 MHz
WDW                  EM
SSB                   0
LB                 0.30 Hz
GB                    0
PC                 1.00
PARVATHI-6
BRUKER
AVANCE II 400 NMR
Spectrometer
SAIF
Panjab University
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Current Data Parameters
NAME         Jan13-2012
EXPNO               170
PROCNO                1
F2 - Acquisition Parameters
Date_          20120113
Time              14.41
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG            zg30
TD                65536
SOLVENT           CDCl3
NS                    8
DS                    2
SWH           12019.230 Hz
FIDRES         0.183399 Hz
AQ            2.7263477 sec
RG                  128
DW               41.600 usec
DE                 6.00 usec
TE                292.9 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                10.90 usec
PL1               -3.00 dB
SFO1        400.1324710 MHz
F2 - Processing parameters
SI                32768
SF          400.1300071 MHz
WDW                  EM
SSB                   0
LB                 0.30 Hz
GB                    0
PC                 1.00
PARVATHI-7
BRUKER
AVANCE II 400 NMR
Spectrometer
SAIF
Panjab University
Chandigarh
avtar_saifpu@yahoo.co.in  
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RG                  128
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TE                292.9 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                10.90 usec
PL1               -3.00 dB
SFO1        400.1324710 MHz
F2 - Processing parameters
SI                32768
SF          400.1300071 MHz
WDW                  EM
SSB                   0
LB                 0.30 Hz
GB                    0
PC                 1.00
PARVATHI-7
BRUKER
AVANCE II 400 NMR
Spectrometer
SAIF
Panjab University
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NAME         Jan13-2012
EXPNO               180
PROCNO                1
F2 - Acquisition Parameters
Date_          20120113
Time              14.46
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG            zg30
TD                65536
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Compound 10 
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Table: 9 
MASS spectral study of the compounds synthesized 
 
 
Compound 
Code 
Molecular 
ions 
1 306.15(306) 
2 323.14(322) 
3 308.13(308) 
4 326.09(326.5) 
5 292.13(292) 
6 380.13(380.1) 
7 396.13(396.1) 
8 382.11(382.4) 
9 400.08(400.6) 
10 366.08(366.4) 
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Compound- 1 
 
Compound-2 
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Compound-3 
 
 
 
Compound -4 
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Compound-5 
 
 
 
Compound-6 
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Compound-7 
 
 
 
Compound-8 
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Compound-9 
 
 
 
Compound-10 
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                         5.4 Results of In-vitro biological activity 
     A)  In-vitro cytotoxicity by MTT assay 
       Figure:1  
In-vitro Cytotoxicity of compounds 7 
 
Control 
 
 
Compound-7 
 
   
           0.1µm     1.0 µm 
 
   
         10 µm     100 µm 
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            Figure:2 
In-vitro Cytotoxicity of compounds 10 
Control 
 
 
Compound-10 
 
  
0.1 µm     1.0 µm 
 
 
 
  
10 µm    100 µm 
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Table10 – Invitro cytotoxicity compound against The human colorectal carcinoma 
cell line (HCT116)  data 
comp 
code 
Conc 
(µM) 
absorban
ce 
% 
inhibitio
n 
IC50 
 
R
2
 
1 0.1 0.442333 0 >100 
µM 
- 
1.0  0.419667 5.124341 
10  0.405333 8.364732 
100  0.367333 16.95554 
2 0.1 0.442 0.075358 >100 
µM 
- 
1.0  0.435 1.657875 
10  0.412 6.857573 
100  0.322333 27.12886 
3 0.1 0.437 1.205727 >100 
µM 
- 
1.0  0.400333 9.495102 
10  0.370667 16.20196 
100  0.267333 39.56292 
4 0.1 0.440667 0.37679 >100 
µM 
- 
1.0  0.432333 2.260739 
10  0.421 4.822909 
100  0.334333 24.41598 
5 0.1 0.457 -3.31575 >100 
µM 
- 
1.0  0.441 0.301432 
10  0.417667 5.576488 
100  0.342 22.68274 
6 0.1 0.462333 -4.52148 >100 
µM 
- 
1.0  0.418333 5.425772 
10  0.380333 14.01658 
100  0.266 39.86436 
7 0.1 0.437 1.205727 35.72 
µM 
0.9764 
1.0  0.370667 16.20573 
10  0.267333 39.56292 
100  0.180666 59.15611 
8 0.1 0.806333 -2.71762 >100 
µM 
- 
1.0  0.769333 1.995754 
10  0.738667 5.902335 
100  0.633333 19.32059 
9 0.1 0.794333 -1.18896 >100 
µM 
- 
1.0  0.779667 0.679406 
10  0.724 7.770701 
100  0.610667 22.20807 
10 0.1 0.443333 -0.22607 79.56 
µM 
0.9927 
1.0  0.420667 4.898267 
10  0.397667 10.09797 
100  0.195 55.9156 
                                                                                                  Results & Discussion 
 
Dept. of Pharmaceutical Chemistry, MMC, Madurai Page 98 
 
 
 
 
 
Determination of cyto-toxicity by MTT assay on HCT116 
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  B) Results for In-vitro anti-inflammatory  of synthesized compound 
Table-11 
  
comp. Code Absorbance value 
(Mean ± SEM) 
Inhibition of 
denaturation (in 
%) 
Control 0.070±0.002 - 
1 0.096±0.002 37.14 
2 0.118±0.002 68.57 
3 0.081±0.002 15.71 
4 0.114±0.002 62.7 
5 0.097±0.0050 38 
6 0.086±0.003 22.85 
7 0.125±0.003 78.57 
8 0.091±0.003 30 
9 0.121±0.004 72.8 
10 0.123±0.003                     75.71 
Ibuprofen 0.130±0.002 85.71 
 
N=3, Inhibition of de-naturation (in %) is represented by Mean ± SEM  
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                     C) Zone of Inhibition of Antibacterial activity 
          Figure 3 
                  compound 10 showing inhibition at 150mcg/ml 
 
                  Escherichia coli                                               Klebsiella pneumoniae 
 
 
                       Proteus mirabilis   Pseudomonas aureoginosa 
 
 
                                                  Staphylococcus. aureus  
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Table-12, Anti- Microbial Activity data 
Comp. 
code 
conc 
(µg/mL) 
Zone of inhibition in mm 
E. coli S. 
aureus 
P. 
aeruginosa 
K. 
pneumoniae 
proteus 
mirabili
s 
6 150 
 
8 9 10 7 7 
7 150 
 
9 9 11 12 8 
8 150 
 
10 9 8 8 9 
9 150 
 
9 8 11 9 10 
10 150 
 
22 20 24 23 8 
standard 
 
30 25 22 26 24 23 
control 00 
 
00 00 00 00 00 
 
             Standard -------     ciprofloxacin 
              Control   --------   DMSO 
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DISCUSSION 
 The molecular design of synthesized compound were done by using osrisis     
property explorer. The toxicity assessment, drug score and drug likeness were 
predicted by  osiris  reveals that all synthesized compounds are under safety 
margin.The results are shown in table-.5  
 The Lipinski rule was predicted for all synthesized compound using 
“Chemdoodle”. It shows no violation in basic properties. It’s proves that the 
synthesized molecule has ability to reach the target site for the action. It conclude that 
the molecules have positive nature on ADME character. The results were shown in 
table-6 
 Based on the literature review some novel derivatives of quinoxaline -2-one 
were synthesized. All the synthesized compounds were purified by re-crystallization. 
The structures of the synthesized compounds were confirmed by IR spectra, 
1
H-NMR 
spectra and Mass spectra. The results were shown in table-7 , 8 & 9. 
  Melting Point 
 All synthesized compound’s melting point and its reactants melting point were 
recorded by open capillary tube method. All  the reactant and obtained products were 
differ in their melting point. It clearly indicates that the formation of a new chemical 
entities. The melting point values are given in table -3. 
Thin Layer Chromatography 
 Thin layer chromatography techniques were performed for all synthesized 
compound as well as the parent compounds, all synthesized compounds gave a single 
spot whose Rf values are different from their reactants. It ultimately shows that the 
compound’s identity and completion of the reaction. The Rf value are given in table-3 
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Infra Red Spectra 
 Infra red spectroscopy was taken for all the synthesized compounds .The 
characteristics absorption peaks were observed for all relevant groups. The absorption  
peak around  1600-1500 cm-1 indicates the formation of CH=N Schiff bases. C=O 
stretching vibration around 1670 cm-1 ,N-H stretching  was observed at 3300-3500 
cm-1,CH2-S stretching was observed at 1410-1490 cm-1, aromatic spectra was found  
near 3040 cm-1,759 cm-1 for C-Cl , C-N stretching at 1247 cm-1 and all other 
relevant groups absorption were observed for all the synthesized compounds. 
1
H Nuclear Magnetic Resonance 
    
1
H
  
Nuclear Magnetic Spectra were taken for all the synthesized compounds 
.Aromatic protons were observed  at 6.68-8.138 ppm and CH=N proton  was observed 
at 9.90-9.97ppm, for all the synthesized compounds. It further established the 
structure of compounds.  
Mass Spectra 
              The mass spectra of these compounds are showed molecular ion peaks 
corresponding to their molecular formula. 
Anticancer activity  
    All the synthesized compounds were tested  for invitro anticancer activity by 
MTTassay .Among the synthetic derivatives compound 7 and compound 10 possess 
cytotoxicity against the Human Colorectal Carcinoma cell line (HCT116). IC50 and 
R
2
 for compound 7 and compound10 shows 35.72µm, 0.9764 and 79.56 µm, 0.9927  
.The other  compound show more than 100µm. The results were shown in table-10. 
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Anti inflammatory activity 
All of the newly obtained compounds  were  tested for in vitro anti-inflammatory 
activity by protein denaturation technique. From the results of anti-inflammatory 
activity  it has been found  that compound 7, compound 9,compound 10  showed 
maximum activity when compared to Ibuprofen. It was also observed that compound 
2 & compound4 exhibit better activity. The remaining compound showed weaker 
activity. The results were shown in table-11. 
 
Antibacterial activity 
 The synthesized compounds of 6-10  were screened for anti bacterial activity 
at the concentration of 150 mcg/ml using DMSO as a solvent against the organism’s 
Staphylococcus aureus, Pseudomonas aureginosa, Proteus mirabilis, Klebsiella 
pneumonia & Escherichia coli by using disc diffusion technique .The result shows 
that compound10 showed  displayed  maximum activity against all the organism. The 
results were shown in table-12. 
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                                 Summary and Conclusion 
 
1. Preliminary screening of novel quinoxaline 2-one was done by using Osiris                           
property explorer and Chemdoodle software. 
2. The present work describes the synthesis of series of some 3-{[2-({(E)-                                  
[substituted) phenyl] methylidene} amino) ethyl] amino} quinoxalin-2(1H)- 
one derivatives and 3-({2-[2-(substituted phenyl)-4-oxo-1,3-thiazolidin-3-
yl]ethyl}amino)quinoxalin-2(1H)-one using 0-phenylene diamine   and oxalic 
acid as starting material. 
3. All the synthesized compounds were purified and characterized by the IR, 
NMR and MASS spectral datas. 
4. The synthesized compounds were found to be identified by TLC. 
5. The spectral datas were coinciding with the structure of synthesized 
compounds.  
6. All the relevant peaks were identified in all the spectras. 
7. The synthesized compounds were screened for Invitro anticancer, anti-
inflammatory and antimicrobial activity. 
8. The result obtained showed that synthesized compound 7 and compound 10 
possesses cytotoxicity against cancer cells. It proves that suitable structural 
modification will have to be carried out to get novel compound having potent 
anticancer activity with least effect on normal cells. 
9. As per invitro anti inflammatory assay (protein denaturation). The synthesized 
compound (7,9,10 ) shows significant anti inflammatory activity.The result 
from present study shows that introducing thiazolidinone nucleus to the 
quinoxaline-2-one and aromatic ring having methoxy group  increases the 
activity . A further study (Toxicological study and in vivo Pharmacological 
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screening) on this compounds suggests attractive starting point to find new 
lead compounds with potential improvements, ultimate use as pain reliever. 
10. The synthesized compounds were screened to obtain Zone of inhibition.  
11. The antimicrobial activities of the compounds were compared with standard 
drug Ciprofloxacin. 
12. Among the synthesized derivatives compound 10 were found to be good in 
antimicrobial activity. Thus based on the above observations we can conclude 
that only at high concentrations, the compound(6,7,8,9) may act as 
antibacterial activity as compared to the standard drug. 
13. The entire study reveals that the compounds will be modified structurally 
based on substitution  and the difference in activity can also determined.By 
incorporating many more ring system to the quinoxaline  nucleus  could lead 
to  more potent and highly active compound. 
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